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Abstract
Drug resistant microbes are a considerable challenge for modern medicine to
overcome. The research described in this dissertation involved development of lipid flippase
inhibitors and investigating their potential as antimicrobial agents against various drug
resistant microbes. The microbes primarily investigated were methicillin resistant
Staphylococcus aureus (MRSA) & Cryptococcus neoformans. Chapter 1 reviews the
historical perspective and summarizes the current state of the field of research. In Chapter 2,
the design space of an antimicrobial peptide known as humimycin was explored and the
effects of modifications on its structure were observed against MRSA. Several key
observations resulted. Most notably, the nanoparticles formed by the drug in solution are a
likely contributor to the ability for various versions of the peptide to work synergistically
when mixed in checkerboard assays. Chapter 3 details the investigation of a P4 type ATPase
flippase inhibitor as an antimicrobial agent against C. neoformans and to potentiate the effects
of Caspofungin. Efficacy of the peptide was observed in vitro against the wild type strain.
Annexin assays and confocal microscopy provide evidence towards the underlying
mechanism of activity, relating to phosphatidylserine distribution in the membrane. Flippase
inhibitors are drugs ripe for investigation due to their antimicrobial potential against drug
resistant microbes.
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Forward. What is life?
What is life? There are competing definitions of life. NASA, from an astrobiology
perspective, defines life as inclusively as possible by describing it as a chemical system
capable of Darwinian evolution. Some definitions of life list sets of behavioral observables
required to be considered life like metabolism, homeostasis, and reproduction. Other
definitions incorporate the special role played by carbon and water.1 Key questions are raised
by each of the various definitions proposed, what is the fundamental unit of life? What
constraints are imposed by accepting a specific definition? To answer the first question, I will
define life as a carbon-based biological system capable of propagating itself into the future
whose fundamental unit is a cell that possesses a metabolism, can respond to stimuli to
maintain homeostasis, and stems from a lineage originating naturally from abiotic conditions
(abiogenesis), classified α-life.
A classification scheme of life in this way allows for varying levels of stringency to
be applied while still maintaining clearly defined boundaries for fringe case cutoffs. In this
classification scheme, silicon-based life would not be considered alive in the α-life perspective
because it is not carbon based. Biological entities like prions and viruses considered nonliving on their own from the perspective of α-life because they don’t fit every criterion, can
be considered alive from the perspective of another classification, β-life. If humans create
cellular life in a test-tube, it would be considered synthetic, σ-life.2 If humans create an android
like commander Data from “Star Trek, Next Generation”, it can be classified as Δ-life. Such
a strategy of classifying entities by some arbitrarily chosen constraints already exists when
considering taxonomic classification of organisms. To answer the second question, the
constraints imposed by defining words allows the users of a language to effectively
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communicate concepts and their relationships to one another in an unambiguous manner. In
this way ideas can be precisely conveyed. The answer to the question of “what is life” really
depends upon what kinds of parameters you want to optimize and what utility is gained by
those optimizations. Science after all goes hand in hand with categorizing things and capturing
the subtlety and nuances of our natural world.
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Chapter 1. Historical
In this chapter, the historical perspectives and prior art are discussed.
§1.1. Drug resistant microbes
There are many examples of drug resistance arising ubiquitously in microbial
organisms that are sensitive to the antibiotics modern civilizations have come to enjoy. In
addition to the over prescription of drugs to people, antibiotics are heavily used in our food
supply and are also found in wastewater.3–7 Drug resistant, pathogenic fungi in particular are
more challenging to address in clinical settings than their bacterial counterparts because
animals and fungi are both eukaryotes. Fungi and animals share much more underlying
biochemistry than animals share with bacteria.8 This close relationship means there are fewer
targets to choose from that will not produce unintended effects in the patient in a clinical
setting. In fact, there are only three classes of antifungal drugs on the market today,
echinocandins, azoles, and polyenes.9 Fungal infections account for over 1.4 million deaths
per year globally.10 Some examples of the more common problematic fungi are Aspergillus
fumigatus, Cryptococcus neoformans, and three species in the genus Candida, C. auris, C.
albicans, and C. glabrata.11 The centers for disease control (CDC) reported a list of current
and emerging antibiotic resistant (AR) threats in the AR threats report, 2019.12
The persistent presence of antibiotics in the environment has resulted in selective
pressure towards AR strains of microbes. The process of artificially applying selective
pressure to generate microbial resistance to an antibiotic is routinely done in the lab to seek
out the genetic basis for drug resistance. There are two general categories of drug resistance
in microbes, intrinsic and acquired.11,13 Some intrinsic and acquired resistance mechanisms
overlap. Intrinsic, or primary drug resistance is somewhat analogous to the innate immune
1

response in mammals. These stress response pathways include biofilm formation, cell
envelope modifications, and activation or deactivation of transporters. Generally, there is
activation and use of cellular machinery that is already in place. Acquired resistance involves
changes to the deoxyribonucleic acid (DNA) to respond to stress. These changes can include
upregulation of gene expression, pathway alteration, single nucleotide polymorphisms
(SNPs), and aneuploidy.
The rapid ability of microbes to adapt to stressful stimuli and the high monetary price
and opportunity cost of developing other pharmaceuticals are the most significant hurdles to
addressing antibiotic drug resistant microbes with market solutions. Since smallpox was
eradicated by the beginning of the 1980s and vaccine development for other harmful
pathogens was well underway, it was thought the war on pathogens was won. Most big
pharmaceutical companies began shifting antibiotics teams of their research and development
(R&D) departments to researching treatments for chronic conditions like diabetes and high
blood pressure which require life-long, daily, maintenance therapy. By the early 2000s, only
a handful of pharmaceutical companies remained in the antimicrobial R&D field.14 In this
chapter of the dissertation the research conducted is put into context of the broader field of
antibiotics.
§1.2. A tale of two drugs
The primary focus of this work is exploration of the design space of an antimicrobial
peptide (AMP) known as humimycin, and the development of a novel antifungal peptide
(AFP) dubbed AW9-Ma. These two peptides’ putative mechanism of activity is the ability to
inhibit their target flippase proteins. To better understand the context of these developments,
application, and potential for resistance to these novel antimicrobial drugs, two case studies
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are analyzed on well characterized antibiotics daptomycin (DAP) and vancomycin (VANC).
In Chapter 2, β-lactams, broadly known as penicillin are discussed. In Chapter 3, antifungal
glucan synthase inhibitors, broadly known as echinocandins are discussed.
Daptomycin , Figure 1, is an example of an AMP based drug originally discovered by
scientists at Eli Lilly (Indianapolis, Indiana) via traditional broth fermentation extractions of
a bacterial actinomycete, Streptomyces roseosporus, in the 1980s. It has broad spectrum
activity against gram-positive bacteria.15 Like many other antibiotic drugs of last resort it is
classified as a nonribosomal product (NRP) because it is generated by a synthetase instead of
the ribosome of its host bacteria.16,17 Upon close inspection of the structure, several unusual
features become obvious. DAP is a 13 amino acid, cyclic, lipidated peptide, containing several
non-proteogenic amino acids. It would be unlikely this product could be made via a ribosome
due to the way in which ribosomal proteins are synthesized. The corresponding genetic codons
and tRNA for some of the amino acids do not naturally exist.18
Daptomycin is a calcium dependent pore forming peptide (PFP) that accumulates on
the inner surface of membranes containing the negatively charged phospholipid
phosphatidylglycerol (PG). As the name suggests, it forms pores in bacterial membranes
causing permeability and leakage. It is used to treat methicillin resistant Staphylococcus
aureus (MRSA), and VANC resistant Enterococcus (VRE).19 DAP resistance (DAP-R) in
VRE was discerned by comparing the genomes of DAP-R and DAP susceptible strains of
Enterococcus. Mutations in genes coding for proteins associated with two different systems
were observed, i) stress response proteins, ii) membrane phospholipid metabolism proteins.20
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Figure 1. Structure of DAP, C72H101N17O26, 1619.7 g/mol. All figures provided were created
by the author of this dissertation unless otherwise noted.
Protein systems known as LiaFSR and YycG control the cell envelope stress response,
mediating cell wall remodeling and membrane fluidity. These processes have been associated
with antibiotic resistance in general. Khan et al. 2019, reported a protein dubbed LiaX that
mediates the activity of LiaFSR in E. faecalis, it is a membrane spanning protein that detects
AMPs with its exofacial exposed nitrogen terminus (N’).21 DAP-R in S. aureus, on the other
hand, has been associated with the bifunctional membrane protein MprF that acts both as a
synthase and flippase (technically a floppase) for lysyl-phosphatidylglycerol (LysPG), a
4

positively charged phospholipid. The SNP that reliably led to DAP resistant S. aureus was
T345A in the substrate binding domain of the MprF flippase component, suggesting the
flippase mutant induced resistance by an exclusionary mechanism.22,23

Figure 2. Structure of VANC, C66H75Cl2N9O24, 1449.3 g/mol
Like the lipopeptide DAP, vancomycin (VANC) is an antibiotic of last resort used to
treat penicillin resistant bacteria like MRSA and Clostridium difficile.24 VANC, the first
glycopeptide antibiotic (GPA) of its kind was discovered in 1958 by scientists at Eli Lilly. It
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is a natural product extracted from a soil dwelling actinobacterium Amycolatopsis orientalis
(originally identified as Streptomyces).25 Unlike DAP, VANC lacks a fatty acid tail (FAT),
Figure 2. Subsequent generations of glycopeptides are semisynthetic. VANC inhibits
peptidoglycan biosynthesis in bacteria by forming hydrogen bonds with the extracellular
amino acid component of peptidoglycan, impeding the cross-linking reactions required to
polymerize lipid II.26 Resistance to VANC in VRE is due to amino acid substitutions of the
pentapeptide portion of the peptidoglycan precursor, lipid II, thus avoiding the mechanism of
activity.27 It is believed that most VANC resistance is acquired a result of horizontal gene
transfer from the host of the VANC producing actinobacterium to pathogenic microbes.28

There are several key limitations of traditional broth fermentation techniques.
Traditional techniques require that the microbes are culturable under lab conditions, and that
the desired metabolome or proteome is expressed under lab conditions. A vast array of
biological, metabolic, and proteomic diversity is not accessible via lab cultures. Modern
approaches to antimicrobial discovery aim to address the limitations of traditional approaches
by using bioinformatics and computational biology to identify new lead targets and ligands.29
These techniques utilize an array of different computer software and databases to predict
primary sequences and higher order protein structures from DNA sequences, binding of
ligands to targets, and structures of small molecule, natural products from synthetase
pathways.30–33 The DNA available to analyze by these techniques has been supplemented in
recent years with the advent of metagenomics, which is the study of environmental DNA
(eDNA).34
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It was traditionally hypothesized that drug resistance to AMPs was not possible due to
the physiological cost required by cells to adapt their membranes to be resistant to AMP
activity.35,36 However there is growing research that shows AMP resistance can occur.37 It is
the challenge of modern medicinal chemists to identify new antimicrobial targets, and
discover new molecules, drug formulations, treatments, and ways to leverage activity of
previously known systems or pathways for antimicrobial purposes.38 In Chapter 3, a novel
drug discovery pipeline is discussed wherein a 3-step process was used to discover a new
AFP, an AMP that targets the pathogenic fungi C. neoformans.

§1.3. Models of AMP activity
AMPs are types of membrane active peptides (MAPs) that exert their antimicrobial
activity on the membrane of an organism. The other class of MAPs named cell penetrating
peptides (CPPs) and spontaneous membrane translocating peptides (SMTP) transport cargo
across a membrane to internal cellular targets.39,40 A common strategy to identify the fate of
the peptide is to label it with a fluorophore and analyze stained cells with a confocal
microscope. If the peptide is a CPP, the fluorescence will be imaged inside of the cell,
specifically inside vesicles or other intracellular compartments. If it is a SMTP it will be found
exclusively in the cell cytosol. Finally, if the peptide is an AMP, it will be localized to the
membrane.41,42 Some AMPs, aptly named PFPs, aggregate on the membrane surface forming
pores leading to lysis. Pores formed vary in morphology from toroidal and barrel-stave pores
that work via carpet or detergent-like disruptions. Vesicle leakage assays are a commonly used
tool to screen the lytic activity of AMPS against vesicles, a common model for membranes of
varying compositions. Properties like hydrophobicity and sequence specificity can be tuned
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to increase membrane partitioning for specific vesicle compositions suggesting a possible
innate targeting strategy for specific cell types and tissues.43
The first AMP, discovered in 1939, dubbed gramicidin, was a natural product extract
from a soil dwelling Bacillus. It was shown to have broad spectrum activity against grampositive bacteria.44 More than 200 currently known AMPs are human defense proteins, many
are associated with the immune system.39 AMPs have even been shown to be effective at
treating viral diseases like dengue fever.45
A quintessential example of an AMP is the principal component of bee venom,
melittin. It is a peptide composed of 26 L-amino acid residues and adopts a bifacial α-helix,
one side is polar, the other side, hydrophobic. Though there is still some debate as to the exact
mechanism of activity, melittin is generally accepted to act as a PFP that disrupts the
membrane and lyses the cell leading to cell death.46 It was demonstrated to be very hemolytic
in the late 1950s, and its antimicrobial activity against penicillin-resistant Staphylococcus was
reported in the 1960s.47,48 There is even a report of melittin inhibiting cancer growth.49

§1.4. Drug synergy
Drug synergy arises from targeting different components of the same underlying
biochemical pathways. Synergy can be achieved in a few ways. The simplest approach is to
mix individual drug components in solution like in a checkerboard assay or fractional
inhibition concentration (FIC) assay. The mathematical measure of drug synergy is a unitless
value called the FIC index, Equation 1.50
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𝐹𝐼𝐶 𝐼𝑛𝑑𝑒𝑥 =

𝐹𝐼𝐶𝐴
𝐹𝐼𝐶𝐵
+
𝑀𝐼𝐶𝐴 𝑀𝐼𝐶𝐵

Equation 1.

Effect

FIC index ranges

Sample calculations

𝑠𝑦𝑛𝑒𝑟𝑔𝑦:

𝐹𝐼𝐶 𝑖𝑛𝑑𝑒𝑥 < 0.5

(64 + 32) = 0.080, (64 + 32) = 0.38

𝑎𝑑𝑑𝑖𝑡𝑖𝑣𝑒 𝑒𝑓𝑓𝑒𝑐𝑡:

0.5 ≤ 𝐹𝐼𝐶 𝑖𝑛𝑑𝑒𝑥 ≤ 1

(64 + 32) = 0.500, (64 + 32) = 1.00

𝑛𝑜 𝑒𝑓𝑓𝑒𝑐𝑡:

1 < 𝐹𝐼𝐶 ≤ 2

(64 + 128) = 1.004, (64 + 128) = 2.00

𝑎𝑛𝑡𝑖𝑠𝑦𝑛𝑒𝑟𝑔𝑦:

𝐹𝐼𝐶 𝑖𝑛𝑑𝑒𝑥 > 2

1

2

16

4

16

8

32

16

64

0.5

64

128

128

0.5

128

128

( 64 + 128) = 2.004, ( 64 + 128) = 3.00

There is some debate as to the correct interpretation of FIC indices. Some argue that
any FIC index less than 1 is classified “synergy” and anything greater than 1 is “anti-synergy”.
Others argue that only FIC indices less than 0.5 are synergy and values between 0.5 and 4 are
“additive or indifferent”. One could argue that the situation is more nuanced, with different
effects being observed at different FIC index ranges. A more detailed explanation is beyond
the scope of this dissertation. Due to the commonly accepted consideration of two-fold error
plus or minus on each minimum inhibitory concentration (MIC) assay and checkerboard
result, it is prudent to use more stringent cutoffs to reduce the likelihood of type I error (false
positive). For the scope of the work presented here only drug combinations resulting in FIC
index < 0.5 are considered synergistic (a multiplicative effect), while FIC indices between 0.5
and 1 are considered an additive effect. FIC indices between 1 and 2 are considered no effect,
or indifference. FIC indices greater than 2 are anti-synergy.
A second more elegant approach to achieve drug synergy is through a process called
bioconjugation. Bioconjugation is a class of reactions that form covalent bonds between two
molecules, at least one of which is a biomolecule like a lipid, carbohydrate, nucleic acid, or
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protein. A diverse range of bioconjugates are accessible via synthetic routes due to the
development of orthogonal protection schemes that prevent excessive side reactions and
byproduct formation. Large scale production and experimentation of these novel compounds
is made more accessible than ever with the implementation of heterogenous, solid phase
synthesis and microwave assisted synthesis, each of which greatly enhances efficiency and
overall green chemistry of the process. In this work, both processes are used to produce AMPs.
Conjugating FATs of the correct length to peptide backbones was demonstrated to tune a
peptide’s ability to act as an inhibitor against specific pathogens.
§1.5. Cell membranes and cell physiology
The membrane is a mechanical barrier that differentiates the inner compartment of a
cell from the external environment. Compartmentalization, a defining feature of living
organisms, provides an envelope in which entropy can be controlled. Low entropy is another
distinguishing feature of living systems. Even the most primitive cells are highly ordered and
structured systems. The imbalance of entropy inside and outside the cell is maintained by the
metabolism of highly ordered food molecules gathered from the environment by phagocytosis.
Cells metabolize food into adenosine triphosphate (ATP) and starting materials for anabolic
pathways to build and maintain the various cellular structures.51,52
The fluid mosaic model describes a cell membrane as existing in a liquid-like phase.
In this model lipids move freely and quickly distribute tension and pressure applied. This
model was tested by Shi et al. 2018, by using sensors capable of detecting membrane tension
in mammalian cells. Observations revealed the fluid mosaic model poorly describes
mammalian cell membrane function because the presence of a cytoskeleton and
transmembrane proteins make the membrane act more like a 2 dimensional gel than a liquid.53
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Understanding of membrane physiology is still in the early stages. For example, Pavel et al.
2020, discovered membrane lipid rafts and TREK proteins were responsible for the bioactivity
of hydrophobic anesthetics.54 Scientists have been trying to understand the mechanism of
action of anesthetics since they were first used in the 1800s.55 Membranes also help to
maintain electrical gradients, for example action potentials in neuronal axons are propagated
by activation of sodium and potassium channels facilitating the flow of metal ions into the
cell.56
Membrane

bilayers

are

distinctly

partitioned

in

eukaryotes.

Glycolipids,

phosphatidylcholine (PC), sphingomyelin, and cholesterol are primarily located on the
exofacial

leaflet.

Phosphatidylserine

(PS),

phosphatidylethanolamine

(PE),

and

phosphatidylinositol are primarily located on the cytofacial leaflet. Lipid composition
between organisms greatly varies and can play a role in drug susceptibility.19,57 Lipid gradients
have been increasingly found to contribute to physiological processes in both fungi and
animals. Alterations of lipid gradient and membrane composition can occur in response to
stress. Membrane lipid asymmetry is vital for organelle shape and dynamics, vesicle budding
and trafficking, membrane protein regulation, membrane stability and permeability, cell
signaling, blood coagulation, apoptosis, fertilization, and bile and cholesterol homeostasis in
mammals.58 Lipid gradients and associated pathways play a hand in drug resistance of
microbes and contributes to quorum sensing in fungi.59
While lipids can freely move in lateral directions, uncatalyzed transverse movement
across the membrane bilayer is exceedingly slow, on the order of hours to days. This is due to
the large energy of activation required to overcome the unfavorable interaction between the
inner hydrophobic membrane region and the hydrophilic head group of the phospholipid. This
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process is greatly enhanced by three types of membrane proteins, flippase, floppase, and
scramblase. Formally defined, the flippase translocates components from the exofacial side of
the membrane to the cytofacial side of the membrane. The floppase translocate components
from the cytofacial side of the membrane to the exofacial side of the membrane. The
scramblase translocates components between both sides of the membrane in an ATPindependent manner.60,61 A relatively recent and major breakthrough in the field of bacterial
physiology was the identification and eventual structure elucidation of Murj, a lipid flippase
responsible for translocating lipid II in Escherichia coli. Lipid II is the precursor to
peptidoglycan, a principal component of bacterial cell walls. Translocation of lipid II from the
cytofacial side of the membrane to the exofacial side of the membrane is a critical step in the
continued growth and polymerization of the cell wall in bacteria because lipid II does not
readily diffuse through the membrane on its own.62–64
P-type flippase proteins require ATP to function. There are 5 categories of P-type
ATPase flippase proteins. Type 1-3 (P1 – P3) are associated with movement of metal ions. The
type 4 (P4) flippase is associated with movement of lipids. The substrate of P5 ATPase flippase
proteins have not yet been identified. Like the P4 flippases, certain floppases known as ATP
binding cassette, and ABC transporters are also ATP dependent lipid transporters.
Scramblases randomly distribute phospholipids about either face of the membrane in the
presence of Ca2+.58 This process contributes to coagulation in RBCs and provide apoptotic
“eat me” signals from damaged cells to macrophages in mammalian tissues.65
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§1.6. Tools of the trade
Solid phase peptide synthesis (SPPS) was first developed in 1963 by the chemist
Robert Merrifield.66 This chemical process iteratively couples and deprotects the individual
amino acids to generate a peptide attached to an insoluble polymeric bead. Over time, there
have been several iterations of solid supports, protection schemes, and activator molecules
contributing to increased yield, purity, specificity, and productivity. Bead selection is an
important consideration because different variations of beads will produce different types of
carboxy termini (C’) on the final peptide. Rink amide resins yield carboxamide termini and
Wang resins yield carboxy termini. SPPS elongates the peptide from the C’ to the N’, the
opposite direction of protein synthesis in a cell by the ribosome. N’ protecting group (FMOC)
is removed from the growing peptide with a piperidine solution, providing orthogonal
reactivity to those used in removal of amino acid side chain protecting groups like tertiary
butyl (tBu) and tert-butyloxycarbonyl (Boc).67

Figure 3. Core structure of an amino acid. Glycine is the simplest amino acid defined by
this structure with an R group of hydrogen.
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Figure 4. Example of N’ FMOC and side chain tBu protected L-amino acid threonine,
FMOC-Thr(tBu)-OH, C23H27NO5, 397.5 g/mol.
The solid support aspect of SPPS enhances the green chemistry of peptide synthesis
because it reduces the amount of waste generated and time required to isolate the intermediate
products after each coupling or deprotection step. Instead of going through tedious liquid
extraction and recrystallization after each reaction, the products bound to the solid support are
recovered by simple vacuum filtration and undergo subsequent wash steps with clean solvent
that remove any remaining traces of the previous reaction mixture. The microwave component
acts as a highly efficient and tunable heat source. It hastens the various reactions using
comparatively less energy than traditional heating methods like a water bath or sand bath. The
microwave reactor maintains a higher degree of temperature control than convective heating
methods because the radiative heating is controlled by a computer that is monitoring the
temperature of the reaction with a thermal probe.68
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Chapter 2. Humimycins
§2.1. Abstract
The purpose of this project was to explore the design space of an AMP molecule
known as humimycin. Derivatives were synthesized and tested against MRSA. Several key
results were obtained through experimental observations. The humimycins form highly
monodispersed nanoparticles in aqueous solution. The key antimicrobial interactions
occurring are stereospecific. A significantly less expensive derivative with equal potency to
the original molecule was also discovered. Derivatives of humimycin can be mixed in a
formulation for synergistic antimicrobial activity.

§2.2. Introduction
Staphylococcus aureus
S. aureus is a gram-positive, cocci-shaped bacteria native to the microbiome of human
skin. Cultures and cell suspensions may appear orange or gold in color, hence the name
“aureus” for gold. Origins of Staphylococcal infections are both community associated, and
hospital spread. Though these bacteria do not typically infect healthy individuals, infections
can occur if there is a route of entry like a cut on the skin. The exact presentation of the disease
can vary wildly from a mild skin infection to severe sepsis if the infection spreads through the
blood stream. Penicillin is the antibiotic of choice if the strain of Staphylococcus is methicillin
susceptible S. aureus (MSSA), and vancomycin if the strain is drug resistant like MRSA.69
Several factors are attributed to the development of drug resistance in bacteria
including the overuse of antibiotics.70 MRSA is a potentially deadly, community-associated,
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drug-resistant pathogen. Though most serious cases of MRSA present in patients that are
already in a healthcare setting, cases of healthy individuals getting seriously ill or even dying
from MRSA sometimes occur in young athletes participating in contact sports like football or
wrestling.71,72 Outbreaks of MRSA in students on scholastic sports teams can have devastating
effects on teams and athletes.73,74 It is in the interest of public health at large to investigate the
various drug resistance mechanisms associated with drug resistant communal bacteria and
develop new therapeutics to overcome the resistance mechanisms.

β-lactam antibiotics target peptidoglycan biosynthesis
Penicillin was the first β-lactam antibiotic discovered in 1929 by the chemist
Alexander Fleming from cultures of a mold suspected to be Penicillium rubrum.75 This fungus
was later identified by Fleming as P. notatum.76 A confounding factor for years to come was
the fact that there are hundreds of known species in the genus Penicillium, broadly categorized
as either P. chrysogenum or P. rubens.77,78 The original molecule discovered by Fleming is
now known as penicillin F. A related compound, penicillin G, discovered in the USA in
culture extracts of another strain of P. notatum grown in broth enriched with molecules
containing benzyl groups, was found to be more stable and ultimately more easily mass
produced due to the change of a double bond to a phenyl ring.79 Modern usage of the term
penicillin describes both natural and synthetic β-lactam antibiotics that possess a thiazolidine
ring adjacent to the β-lactam core, Table 5. These drugs bind to bacterial proteins known as
penicillin binding proteins (PBPs) and inhibit a transpeptidase responsible for the final step of
polymerizing peptidoglycan from lipid II.80 Discovery of penicillin in its time was so
important that its development was stewarded by the government and side-stepped most of
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the standard hurdles of intellectual property rights and the usual economic resistance of drug
discovery. It is thought that penicillin was such a critical discovery that it helped turn the tide
of World War II in favor of the Allied forces.81
Name
Penicillin F

Found in
extract of
P. notatum 76

Penicillin
G

P. notatum 79

Penicillin
V

P.
chrysogenum

Side chain

Penicillin substrate

78,82

Methicillin

Semisynthetic
83

Table 5. Penicillin, the original β-lactam antibiotic. The core structure consists of a 4-member
β-lactam ring fused with a 5-membered thiazolidine ring. All tables provided were created by
the author of this dissertation unless otherwise noted.
Methicillin, a semisynthetic derivative of penicillin was introduced in the late 1950s
to help treat Staphylococcus infections.83,84 Within two years of its introduction, resistant
strains were reported in England.85 Resistance was linked to a gene SCCmec that codes for an
inherently drug resistant PBP, PBP-2a, mecA in S. aureus. It is believed to have been acquired
by MRSA via horizontal gene transfer.84 While β-lactamases might seem like a defensive
microbial superpower that required defeating, in the mid-1940s these enzymes were utilized
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medicinally to treat penicillin induced anaphylaxis in patients by catalyzing the hydrolysis of
the β-lactam ring to a carboxylic acid functional group that is biologically inert.86
A subset of β-lactam antibiotics, cephalosporins were first discovered about 20 years
after penicillin by the Italian scientist Giuseppe Brotzu from culture extracts of
Cephalosporium acremonium. Originally dubbed mycetin, the drug was eventually developed
into cephalosporin C and released into the market in the 1960s.87 Side chain groups vary
greatly between the specific versions of cephalosporin from small linear alkyl groups to 5 and
6-member heterocycles containing atoms like nitrogen and sulfur. The many different versions
of cephalosporins have a broad activity spectrum against both gram-positive and gramnegative bacteria. Since they act on the same underlying peptidoglycan biosynthetic pathways
as penicillin, similar resistance mechanisms occur. The β-lactamase is a commonly evolved
strategy used by bacteria to break down the antibiotic before it has a chance to bind to PBPs.
Some cephalosporins are not sensitive to enzymatic degradation by β-lactamases, making
them a superior antibiotic in instances that β-lactamases are present.

Figure 5. Cephalosporin substrate, a 4 membered β-lactam ring fused with a 6 membered
1,3-thiazine ring
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Lipid II flippase is linked to β-lactam resistance in S. aureus
A moment is required to acknowledge an inconsistency between the nomenclature
used in the literature and the technical definitions provided in Chapter 1: Murj, the Lipid II
flippase in E. coli is called a flippase however it is technically a floppase. Despite being called
a flippase in the literature lipid II flippase translocates lipid II from the cytofacial side of the
membrane to the exofacial side of the membrane. Flippases are formally defined as carrying
out the exact opposite function, that is translocating lipids from the exofacial side of the
membrane to the cytofacial side of the membrane. It is believed that Sav1754 is the Murj
homolog in S. aureus.62,88,89
A genetic screen identified Sav1754 transcription inhibitors potentiated the effects of
β-lactams implicating the protein in penicillin resistance and the peptidoglycan biosynthetic
pathway.88 Since peptidoglycan biosynthesis occurs on the exofacial side of the membrane, it
is unlikely exclusion is a viable mechanism for resistance. Most likely, the explanation linking
lipid II flippase inhibition with penicillin resistance arises from the underlying biochemistry
of lipid II. By inhibiting the lipid II flippase, lipid II cannot easily be transported to the
exofacial side of the membrane for polymerization. Reducing the concentration of lipid II on
the exofacial side of the membrane makes it the limiting reagent of the cross-linking reaction.
By limiting lipid II availability on the membrane surface, far less penicillin is required to
effectively inhibit the PBPs leading to the reported synergy of humimycin and penicillin
combinations.89
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Exploration of the design space of humimycin
Another example of a NRP, humimycin is a N’ lipidated heptapeptide containing two
D-amino acids with a broad activity spectrum against Firmicutes and moderate activity against
Actinobacteria. It was reported by Chu et al. 2016, Rockefeller University, to have activity
against MRSA strain USA300, MIC = 8 μg/mL. Humimycin was also categorized as a
synthetic bio-informatic natural product (Syn-BNP) since it was a natural product predicted
to exist based on the genes coding for synthetases associated with secondary metabolites in
Rhodococcus equi, a native resident of the human microbiome. Resistance to humimycin was
observed in strains overexpressing SAV1754, and SAV1754 mutants with 16 unique SNPs.89
Existence of this peptide was never experimentally confirmed in broth fermentation because
it is not expressed under laboratory conditions.89,90
Sequence modifications like a FAT scan, alanine scan, and deletion scan revealed that
the presence of all seven amino acids and the identity of the FATs were crucial for antibiosis.
A second-generation peptide dubbed 17S was reported to have enhanced activity overall
compared to humimycin. Even though it had comparable activity against MRSA USA300,
MIC = 8 µg/mL, its use resulted in lower observed resistance rates and improved synergy
when used in combination with carbenicillin. It also had a broader activity spectrum including
VRE. The (S)-3-hydroxymyristic acid in humimycin was retained in 17S. Aromatic amino
acids phenylalanine and tyrosine were substituted for their bulkier cousin tryptophan.91 Since
a few of the modifications previously made seemed somewhat successful it was reasonable to
continue to explore the design space of the drug and observe the effects of various rational
modifications to the peptide on the antibiotic activity against MRSA.92
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§2.3. Methods
Peptide synthesis
All peptides were synthesized using manual solid phase peptide synthesis (SPPS) on
Wang resin. This method entails consecutive rounds of orthogonal coupling and deprotection
reactions that add the individual monomers to the peptide one at a time. Peptides are
synthesized in the lab from the C’ to the N’, the opposite direction of sequences assembled by
the ribosome in a cell. All the reactions were carried out at room temperature. Once the crude
peptides were cleaved off the resin, they were purified using preparatory scale HPLC. Purified
fractions were combined, concentrated, acidified, frozen, and lyophilized to a dry powder.
The resulting products were characterized and analyzed for antimicrobial activity.
Batches were started at the 0.2 mmol scale and split for various modifications after
several amino acids were coupled. Sequences were finished on the 0.5 – 0.1 mmol scale.
Standard FMOC/tBu protection scheme was used for all amino acids. Resin was swollen in
DCM and had the first amino acids double coupled for two hours each. After every reaction
the resin was washed twice with DMF, MeOH, and DCM. Any remaining nucleophilic sites
on the resin were capped with acetyl groups using excess acetic anhydride in the presence of
DIEA. N’ FMOC protection was removed using a solution of 20 % v/v piperidine in DMF.
FMOC-AAs were subsequently coupled to the unprotected N’ using HCTU and DIEA as the
activator and base respectively.
FAT coupling reactions of β-hydroxymyristic acid (β-HMA) used the same coupling
conditions. Myristic anhydride was used in combination with DIEA to couple C14. Reaction
progress was monitored via qualitative Kaiser test. Here, the ninhydrin turns a blue color in
the presence of a free amino group.93,94 The peptide was cleaved in a mixture of 2.5 % H2O,
21

2.5 % TES, and 95 % TFA. Though the reactions are first order with respect to the reactants,
to balance yield, reaction time, and amount of raw materials used, greater than 1:1
stoichiometry of monomer to peptide was used. The stoichiometry in Reaction 1 - Reaction 6
reflect molar proportions used in the lab to synthesize the humimycin peptides.

𝐷𝑀𝐹
2 ℎ𝑜𝑢𝑟𝑠

𝐵𝑒𝑎𝑑 − 𝑂𝐻 + 3𝐹𝑀𝑂𝐶 − 𝐴𝐴 + 3𝐻𝐶𝑇𝑈 + 6𝐷𝐼𝐸𝐴 →

𝐹𝑀𝑂𝐶 − 𝐴𝐴 − 𝐵𝑒𝑎𝑑

Reaction 1. First amino acid was double coupled at room temperature for 2 hr each to ensure
as much of the resin was labeled as possible. For all other amino acids, a subsequent
deprotection reaction was only run if the ninhydrin test was negative.

𝐷𝑀𝐹,
30 𝑚𝑖𝑛

𝐵𝑒𝑎𝑑 − 𝑂𝐻 + 10𝑎𝑐𝑒𝑡𝑖𝑐 𝑎𝑛ℎ𝑦𝑑𝑟𝑖𝑑𝑒 + 20𝐷𝐼𝐸𝐴 →

𝐵𝑒𝑎𝑑 − 𝑂𝐴𝑐

Reaction 2. Capping the unreacted nucleophilic sites of a bead with acetic anhydride at room
temperature for 30 min.

𝐹𝑀𝑂𝐶 − 𝐴𝐴 − 𝐵𝑒𝑎𝑑 + 20%

15 𝑚𝑖𝑛𝑢𝑡𝑒𝑠
𝑣
𝑝𝑖𝑝𝑖𝑟𝑖𝑑𝑖𝑛𝑒 𝑖𝑛 𝐷𝑀𝐹 →
𝐵𝑒𝑎𝑑 − 𝐴𝐴 − 𝑁𝐻2
𝑣

Reaction 3. FMOC deprotection reaction exposing the free amino terminus, room temperature
for 15 min. This reaction was usually run multiple times to ensure quantitative deprotection.
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𝐷𝑀𝐹
1 ℎ𝑜𝑢𝑟

𝐵𝑒𝑎𝑑 − 𝑝𝑒𝑝𝑡𝑖𝑑𝑒 − 𝑁𝐻2 + 𝐵 − 𝐻𝑀𝐴 + 𝐻𝐶𝑇𝑈 + 2𝐷𝐼𝐸𝐴 →

𝐵𝑒𝑎𝑑 − 𝑝𝑒𝑝 − 𝐹𝐴𝑇

Reaction 4. β-HMA FAT labelling reaction. This reaction was double coupled at room
temperature for one hour each, using 1:1 stoichiometry of peptide to FAT. This FAT was the
limiting reagent due to its high price.
𝐷𝑀𝐹
1 ℎ𝑜𝑢𝑟

2𝐵𝑒𝑎𝑑 − 𝑝𝑒𝑝𝑡𝑖𝑑𝑒 − 𝑁𝐻2 + 3𝑀𝑦𝑟𝑖𝑠𝑡𝑖𝑐 𝑎𝑛ℎ𝑦𝑑𝑟𝑖𝑑𝑒 + 6𝐷𝐼𝐸𝐴 →

2𝐵𝑒𝑎𝑑 − 𝑝𝑒𝑝 − 𝐹𝐴𝑇

Reaction 5. Mystic acid labelling. This FAT was double coupled to ensure maximum labeling.
The reaction was run at room temperature for one hour.

𝑣
2.5% 𝐻2 𝑂 2.5% 𝑇𝐸𝑆
𝑣
95% 𝑇𝐹𝐴 1 ℎ𝑟

𝐵𝑒𝑎𝑑 − 𝑝𝑒𝑝𝑡𝑖𝑑𝑒 − 𝐹𝐴𝑇 →

𝑃𝑒𝑝𝑡𝑖𝑑𝑒 − 𝐹𝐴𝑇

Reaction 6. Reaction conditions for peptide cleavage from the solid support. Water and
triethylsilane (TES) were added to the tube first immediately followed by trifluoroacetic acid
(TFA). This reaction proceeded at room temperature for one hour.

Purification
Crude peptide in TFA was concentrated 10 to 20-fold by removing the TFA with a
steady stream of nitrogen gas. The concentrated peptide solution was diluted to 3 mL in 70 %
v/v acetonitrile in water. The mixture was sonicated in a tube for 20 min, filtered through a
0.45 μm filter and injected into the preparatory HPLC. The detector was set to 220 nm to
detect the amide bond backbone of the peptide. Fractions were collected manually. The
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analytes of interest in this case had a significant retention time on the C18 prep column due
to the presence of the FAT as well as lack of hydrophilic or ionized amino acid side chains.
Fractions were analyzed by a UV-Vis nanodrop spectrometer, ND1000 (Thermo
Scientific). Fractions were combined with each other based on the retention time of the sample
in the preparatory scale HPLC as well as characteristic UV-Vis absorbance peaks from the
peptide bonds and aromatic amino acid side chain groups at 220 nm and 280 nm respectively.
The chosen fractions were mixed and concentrated on a rotary evaporator, acidified with
glacial acetic acid to 10 % v/v, frozen in the -80 °C freezer and lyophilized to dry powder.
The purity of the finished product was assessed via analytical HPLC, and the molecular
identity was confirmed via mass spectrometry.

Characterization
Due to the lack of basic amino acid residues like lysine, the humimycin peptides were
not charged enough to detect using the in-house electrospray ionization (ESI) HP1100 mass
spectrometer. To keep costs low, only samples of finished product were sent out for MALDITOF-MS analysis. The purity of the peptides was analyzed in-house by reverse phase HPLC
using a C18 column on a Shimadzu Nexera-i 3D plus instrument. Circular dichroism (CD)
spectra were recorded in-house on the OLIS rapid scanning monochromator (RSM), On-line
instrument systems Inc. DLS analysis of the humimycin nanoparticles was done on a Malvern
Zetasizer at NJIT. More details on the purification and characterization of these samples can
be found in the appendices.
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Peptide stock solution
A mass of 0.5 – 4 mg peptide was weighed out in a sterile Eppendorf tube. The tube
was centrifuged at 3000 rpm for one minute to pack the powder into a solid plug the bottom
of the tube. The peptide was diluted to a concentration of 12.8 mg/mL in filtered DMSO (0.2
μm pore filter tip).

Passaging MRSA
MRSA USA300 isolates were purchased from ATCC. A 10 μL aliquot of stock
microbe solution was diluted 10-fold in 1 mL LB media using a 5 mL culture tube. The
resulting cell suspension was incubated at 37 °C and 250 rpm for 24 hours.

MIC assay
The sample prep consisted of prepping microbes, setting up drug dilutions on a 96 well
plate, inoculating the plate with microbes, and incubating the plate. The data acquisition and
interpretation were done simultaneously because the observations were straight forward. It
was noted whether the experimental wells were consistent with either of the controls or not.
A 50 μL aliquot of LB media was charged to each well of a 96 well plate. An additional
50 μL aliquot of RPMI was charged to the first column. A 2 μL aliquot of peptide-DMSO
stock solution was diluted 50-fold in column 1. The dosed liquid in column 1 was serially
diluted to column 11, transferring 50 μL each time. MRSA inoculating solution was prepared
by diluting 1 μL of freshly grown cells 5000-fold to 5 mL. A 50 μL aliquot of bacterial
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inoculant was charged to each well on the plate except for column 11. Column 11 was the
negative control, column 12 was the positive control.
Inoculated plates were incubated at 37 °C for one day. Incubated plates were inspected
visually for growth. It was noted if the data point was consistent with the positive control,
negative control, or if it was inconsistent with both controls. This procedure was consistent
with the protocols reported by Brady’s group (Rockefeller University) in the original
publication that detailed the discovery of humimycins.89

Checkerboard assay
This sample prep is nearly identical to the MIC assay, except there are four sets of
drug serial dilutions instead of one. Compared to the MIC assay the volumes were doubled to
help reduce the error caused by air bubbles that would sometimes accumulate in the wells
while doing the second set of serial dilutions. Both peptide-DMSO stock solutions were
diluted 2-fold to 6.4 mg/mL in DMSO prior to starting. Each well in the 96 well plate was
charged with 100 μL LB media. An extra 100 μL LB media was charged to each well in the
first column and 8 μL of the first drug stock solution was diluted 25-fold. A 100 μL aliquot of
solution was serially diluted two-fold, 8 times from column 1 to column 8. The extra 100 μL
solution from column 8 was discarded.
Another 100 μL LB media was charged to the first 10 wells in row 1. A 4 μL aliquot
of the second drug stock solution was diluted 50-fold in the first 8 wells of row 1. A 100 μL
aliquot of solution was serially diluted two-fold, 8 times from row 1 to row 8. The extra 100
μL volume from row 8 was added to the wells in column 11. A 4 μL aliquot of each peptide
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stock solution was diluted 50-fold individually in either column 9 or column 10. A 100 μL
aliquot of solution from column 9 and 10, row 1 was serially diluted two-fold, 8 times from
row 1 to row 8. The extra volume of liquid from row 8 was discarded.
The bacterial inoculant was prepared in the same manner as the MIC experiment. Two
μL of freshly cultured bacterial cell suspension was diluted 5000-fold in 10 mL LB media. A
100 μL aliquot of bacterial cell inoculant was charged to every well on the plate except for
column 11. Columns 9 and 10 were the MIC controls of the individual drugs alone. Column
11 was the negative control. Column 12 was the positive control.
The plate was incubated at 37 °C for one day. The plates were inspected visually, and
the results were recorded in a lab notebook. It was noted if the observed growth was consistent
with that of the positive control, the negative control, or neither. FIC index was computed by
summing the ratios of FIC to MIC of both drugs.

§2.4. Results and Discussion
Peptide Summary
A description of each peptide sequence synthesized is provided in Table 6. It is
important to note that peptide 5C and 7A are the original humimycin A and humimycin A1
peptides respectively. Peptide 5B is a FAT modified version of 7A. The fatty acid was myristic
acid (Ma, C14) instead of β-HMA. The raw material used to couple Ma was more than 100fold less expensive than the enantiomerically pure β-HMA. Series 6 peptides are peptide
enantiomers. The following pairs are enantiomers, (6A, 7A), (6B, 5C), (6C, 5B), and (6D,
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7B). Mass spectrometry results are tabulated in Table 7. Purity and retention times are reported
in Table 8. DLS results are tabulated in Table 9.
Name
Short Name
Sequence
Hum W
5A
(S)-β-HMA – WSyFtVV
Hum dehydroxy
5B
Ma – YSyFtVV
Hum A
5C
(R)-β-HMA –YSyFtVV
Hum A1 e
6A
(R)-β-HMA – ysYfTvv
Hum A e
6B
(S)-β-HMA – ysYfTvv
Hum dehydroxy e
6C
Ma –ysYfTvv
Hum w dehydroxy e
6D
Ma – wsYfTvv
Hum A1
7A
(S)-β-HMA – YSyFtVV
Hum w dehydroxy
7B
Ma – WSyFtVV
Table 6. Humimycins derivative sequences synthesized.

Short
Name

Computed m/z
Observed m/z
+1
+2
5A
1128.39
564.70
1128.64
5B
1089.35
545.18
1089.63
5C
1105.35
553.18
1105.63
6A
1105.35
553.18
1105.62
6B
1105.35
553.18
1105.63
6C
1089.35
545.18
1110.5
6D
1112.39
556.70
1133.5
7A
1105.35
553.18
1126.6
Table 7. MALDI-TOF MS analysis of humimycins, tabulated results.

Short name
5A
5B
5C
6A
6B
6C
6D
7A

Purity (%)
220 nm
90
90
80
80
90
95
88.4
97
28

Molecular weight
1127.39
1088.35
1104.35
1104.35
1104.35
1088.35
1111.39
1104.35
1111.39

Comment

Retention time
minutes
13.6
15.2
12.9
13.6
12.9
14.9
17.3
15.4

+1
+1
+1
+1
+1
+1(1Na)
+1(1Na)
+1(1Na)

Table 8. Tabulated purity of humimycin sequences synthesized. Retention time is reported
relative to the injection to compensate for transferring methods between instruments. The
relationship between the gradient program and injection were constant.

Sample ID
Prep Method
Liposome
control
extrusion
5A
1
5B
1
6B
1
7A
1
5B
1
6C
1
5A
1
5A + 7A
2
5B + 7A
2
5A + 7A
3
5B + 7A
3
Table 9. Tabulated DLS results.

Concentration
μg/mL

Particle size
nm

PDI

100
85
128
256
4
4
4
128
128
128
128

123.5
159.3
139.1
119.6
132.8
211.8
158.2
75.68
142
128
153.6
131

0.069
0.088
0.151
0.155
0.117
0.14
0.099
0.223
0.1
0.154
0.114
0.148

Short Name
MIC μg/mL
5A
8
5B
8
5C
64
6A
>128
6B
>128
6C
>128
6D
>128
7A
16
Table 10. Tabulated MIC data of humimycin peptides against MRSA USA300.

Short Name
5A x 5B

FIC μg/mL
2, 1
29

FIC index
0.38

5A x 5C
5A x 7A
5B x 5C
5B x 6A
5B x 6B
5B x 7A
5C x 6B
5C x 7A
6A x 7A
6B x 7A
Table 11. Tabulated FIC data

2, 16
1, 0.5
2, 16
4, 0.5
4, 0.5
2, 4
32, 8
16, 0.5
0.5, 8
16, 4

0.5
0.16
0.5
0.5 – 1
0.5 – 1
0.5
0.5 – 1
0.28
0.5 – 1
0.5 – 1

Humimycin derivatives retained antimicrobial activity
The observed humimycin MIC data is provided in Table 10. When the original
humimycin A1 synthesized in-house was tested against MRSA USA300, MIC values
observed were 16 μg/mL. This result was within the factor of two window for error on 96well plate microdilution assays compared to the original values reported, 8 μg/mL.89 The
tryptophan substitution present in peptide 5A seemed to mildly enhance activity. Cells in the
final well prior to the MIC cutoff looked more stressed and less confluent than the cells in the
other wells. Peptide 5B had comparable activity to that of the original humimycin A1, MIC
of 8 μg/mL. All the peptide enantiomers had an MIC >128 μg/mL. This evidence suggest that
the mechanism of activity is a stereospecific peptide – protein interaction. The peptide
enantiomers should be as effective as the original peptides if a generic pore forming model
described the activity.
In the original literature reporting the humimycins it was decided that sequences with
tryptophan would be synthesized with tyrosine, a smaller aromatic amino acid since the in
silico technique they were using tended to over-express tryptophan.89 One could argue on the
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other hand that presence of tryptophan might be important because it has been observed that
tryptophan residues are highly abundant in interfacial transmembrane helices.95–99 In other
words, high expression of tryptophan residues is naturally observed in regions of
transmembrane proteins that are on the interface between the inside and outside of a
membrane. Since portions of the lipid II flippase appropriately fit this description, it is only
logical that presence of tryptophan residues would be vital for activity of a peptide targeting
interfacial regions of transmembrane proteins. Furthermore, SNPs that confer resistance to
humimycin also primarily occur around the interfacial region of the transmembrane helices,
suggesting these regions are vital for the drug-target interactions.89

Synergy via formulation
The observed FIC indices for mixes of the humimycin peptides are provided in Table
11. Mixtures of humimycin derivatives at different concentrations led to an additive effect or
no effect depending on the peptides used and the concentrations. An additive effect was
always present when mixing the L-amino acid dominant peptides at all concentrations. When
testing mixtures of the D, and L-amino acid dominant peptides there was an additive effect at
low concentrations of the D-peptide and no effect at high concentrations of the D-peptide.

Nanoparticle formulation imparts synergy
CD spectroscopy was initially used in an attempt to elucidate the secondary structure
of the peptide in water, results in Appendix C. Due to a significant amount of light scattering
from the sample, spectral acquisition time was unreasonable, on the order of hours. To further
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investigate this result, the same samples were analyzed again using DLS, results provided in
Table 9 and in Appendix D. It was found that the humimycins form highly monodispersed
nanoparticles in aqueous solution. This result not only explains the long acquisition time on
the CD spectrometer, but also the synergy observed among the various versions of the
peptides.
This result would also explain why the FIC index was a function of concentration of
D-dominant peptides. If only a little bit of peptide was added, it acted as a dopant. The slight
dilution of the drug was made up by the fact that more nanoparticles could be formed with
enough of the active drug that it could still work. Past a certain threshold concentration of
series 6 peptides, the inactive peptides would compete for time in the active site, but only the
active peptide could inhibit growth, reducing the overall antimicrobial activity.
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Chapter 3. Antifungal peptide
§3.1. Abstract
C. neoformans is a problematic pathogenic fungus. It is resistant to caspofungin, a
commonly prescribed antifungal medication. Mutant screening led to a novel resistance
pathway to the antibiotic not previously known, associated with the P4-type ATPase flippase.
This chapter details the research and development of an antifungal peptide targeting this
flippase in C. neoformans. Key results from the initial stages of investigation eventually led
to a peptide dubbed AW9-Ma. This 9 amino acid myristylated peptide inhibited in vitro
growth of the wild type strain H99 at a concentration of 64 μg/mL. Presence of the peptide
sensitized the fungus to caspofungin when combined in a checkerboard assay, FIC index =
0.5. The MIC of caspofungin was reduced to a level equal to that of a susceptible mutant in
the presence of a relatively low concentration of the peptide. Annexin assays showed that
AW9-Ma was a potent flippase inhibitor and caused a significant accumulation of
phosphatidylserine accumulation on the exofacial membrane leaflet.
§3.2. Introduction
Cryptococcus neoformans
Cryptococcus neoformans (Cn) is a drug resistant pathogenic fungus primarily infecting
the central nervous system (CNS) of immunocompromised individuals typically presenting as
fungal meningitis. The fungus enters the body either from direct environmental exposure via
an open wound or from spores inhaled into the lungs.100 Some evidence suggests C.
neoformans binds host plasminogen on its surface to gain passage through the blood brain
barrier (BBB) and infect the CNS.101 Of the 19 different species in the genus Cryptococcus,
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only two are considered pathogenic, Cn and C. gattii. The latter is more pathogenic to healthy
individuals than the former.
C. neoformans is categorized as an encapsulated hetero-basidiomycetous fungus
present in the environment in asexual and sexual phenotypes. Cultures of the yeast form
primarily associated with infections are considered mucoid.102 The meiotic form, originally
identified in 1976 as Filobasidiella neoformans, produce spores.103 Patients with AIDS and
transplant patients are the most at risk of developing this disease. Since Cn is resistant to
echinocandins, treatment strategies are limited to azoles and amphotericin B. Azole activity
against Cn is fungistatic, not fungicidal, so prolonged treatment is required, and resistance can
occur.104 Azole resistance is thought to arise as a consequence of aneuploidy and polyploidy
facilitated mutations.105,106 Treatment with amphotericin B causes serious side effects in the
patient, particularly in the kidneys.107,108 It is in the interest of the most at risk individuals in
society that the scientific community continues to innovate highly effective new antifungal
therapies against C. neoformans that have fewer side effects.
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Figure 6. Structure of fluconazole, C13H12F2N6O, 306.3 g/mol.

Figure 7. Structure of Itraconazole, C35H38Cl2N8O4,705.6 g/mol.
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Figure 8. Structure of amphotericin B, C48H77NO16, 924.1 g/mol.
The azole class antifungals inhibit ergosterol biosynthesis.109 Amphotericin B is in a
class of drugs known as polyenes. It binds to ergosterol in the membrane causing pore
formation, and causes intracellular oxidative stress via reactive oxygen species (ROS), leading
to cell death.110 Ergosterol is the primary sterol in fungal cells, it is an essential mediator of
various cellular processes. It helps to maintain the membrane fluidity and permeability.109,111
Ascomycota, also known as sac fungi, like C. albicans, and A. fumigatus are
pathogenic, Penicillium molds like P. notatum are vital antibiotic producers, and species in
the genus Morchella like M. esculenta are delicious edible morels. Basidiomycota, also known
as club fungi, incorporate a wide variety of species from pathogenic C. neoformans to edible
white button mushrooms Agaricus bisporus and psychedelic species in the genus Psilocybe,
like P. cubensis. There are beneficial and pathogenic species in both phyla. Basidiomycota
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split from the Ascomycota more than 500 million years ago, so it is reasonable to assume
some genetic divergence has occurred over the years.112 Given how long ago these fungi
diverged from each other it would be useful to find conserved traits that can be targeted for
broad spectrum antifungal activity against these pathogenic fungi.
Caspofungin targets the β-D-glucan synthase
In general, fungal cell walls are composed principally of polymers like chitin, glucan,
and mannoproteins.113 A variety of glycosidic linkages have been observed linking together
the glucose monomers of glucan; both α or β anomers have been observed. The predominant
glucan in most fungi is typically (1-3)-β-D-glucan, however Cn and several other pathogenic
species the α anomer is predominant.114 Fungal cell wall biosynthesis is more like plant cell
wall biosynthesis than bacterial cell wall biosynthesis. Unlike bacteria, fungi synthesize the
glucan polymer from the monomer in the cytosol via the catalytic component of the
glucosyltransferase enzyme, FKS. The extending glucan polymer is then released into the
periplasmic space for subsequent polymerization and cross-linking.
The β-D-glucan synthase is a membrane spanning protein ubiquitously found in fungi.
It is composed of several subunits.115 Mutations to amino acids in the catalytic region of the
FKS subunit that facilitates the glucosyl-transfer reaction led to considerable echinocandin
resistance. Additionally, mutations in several other hotspots, a transmembrane helix and two
regions of an exofacial loop region also led to echinocandin resistance suggesting an
alternative mechanism of drug activity other than directly binding to the catalytic site of FKS.
It was proposed the resistance mechanism not directly associated with the catalytic component
might relate to drug transport, but no further models or evidence to support this hypothesis
were provided.116–118
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Caspofungin was the first in a class of antifungal drugs known as echinocandins
(Figure 9 - Figure 12) to be approved by the Food and Drug Administration in the USA. These
drugs inhibit the β-D-glucan synthase, an enzyme responsible for polymerizing the
carbohydrate component of the cell wall in fungus.119–121 Inhibiting this enzyme is a common
antifungal strategy because the glucan synthase and its underlying function is conserved in
most fungi. Gene deletion experiments showed that proteins responsible for building the cell
wall of fungi are necessary for basal function of the cell.112

Figure 9. Structure of caspofungin, C52H88N10O15, 1093.3 g/mol.
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Figure 10. Structure of cilofungin, C49H71N7O17, 1030.1 g/mol.

Figure 11. Structure of anidulafungin, C59H77N7O16, 1140.3 g/mol.
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Figure 12. Structure of micafungin, C56H71N9O23S, 1270.3 g/mol.
C. neoformans wild type (WT) strain, H99, is considered resistant to echinocandins
with reported MICs of 16 μg/mL against caspofungin and 64 μg/mL against cilofungin.
Maligie et al 2005, propose three possible explanations for the resistance, that the target is
resistant, caspofungin is degraded, or caspofungin is excluded.122 They performed assays
optimizing for β-D-glucan synthase activity and showed that the caspofungin is not degraded
and that the target itself is not resistant. There must be a separate mechanism facilitating the
exclusion of caspofungin from C. neoformans.

P4 Flippase is linked to caspofungin resistance in C. neoformans
Research by Huang et al. 2016, Rutgers University, our collaborators showed that a
mutant Cryptococcus strain lacking a gene for the Cdc50 protein, a P4 flippase β-subunit was
susceptible to caspofungin with a reported MIC of 4 μg/mL.123 This mutant strain was dubbed
Cdc50Δ since it lacked the β-subunit of a fungal P4 flippase. Other work has also implicated
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calcineurin, a regulator in the calcium homeostasis pathway in caspofungin resistance.124–126
The resistance mechanisms are all likely unified in an underlying biochemical pathway
connecting calcium concentration, PS distribution and flippase activity, synthase activity, and
the cellular stress response.
A noteworthy review on the topic of P4 flippase proteins was written by Andersen et
al, 2016.58 P4 flippases are conserved in eukaryotic organisms. The structure, function, and
substrate specificity of these proteins have only recently begun to be characterized in model
systems. There are only five total P4 type ATPase flippase proteins in yeast, Drs2p, Neo1p,
Dnf1p, Dnf2p, & Dnf3P; only the deletion of the gene coding for Neo1p proved fatal. The
situation is more complex in mammals. There are 14 different P4 ATPase flippase proteins in
Homo sapiens (Hs). The five subtypes are delineated by phylogenetic similarity.
A large area of research is dedicated to solving what is known as the flippase substrate
problem. In some instances, specificity is determined by the identity of certain key amino
acids in the transmembrane M domains of the flippase α-subunit that are suspected to interact
with the hydrophobic lipid tail, known as the canonical binding model. In other instances,
flippase substrate specificity is determined by key amino acid residues located in the
interfacial region of transmembrane helices that are suspected to interact with the polar head
group of the lipid, known as the peripheral pathway model. The P4-type flippase proteins have
a conserved aspartic acid in their ATP dependent phosphorylation domain, “DKTGT”.58,127
These conclusions were drawn from experiments with fluorophore-labelled
phospholipid analogs containing the fluorophore NBD in conjunction with genetic mutation
screens. Some of the more elegant approaches involve preparing synthetic vesicles with
purified flippases. Many flippase structures reported are closely associated with cell division
41

cycle 50 (Cdc50) proteins. Generally speaking, P4 flippases are categorized as either P4A or
P4B; P4A require the presence of the β-subunit and P4B do not require the presence of the βsubunit.58
The precise role played by the Cdc50 loop region in flippase activity is not well
understood, however cooperativity is suspected. These extracellular accessory proteins are
hypothesized to regulate the flippase activity and provide cooperativity in certain states.
Heterologous expression in mammalian cells has shown that presence of the β-subunit helps
the flippase to fold correctly in the endoplasmic reticulum. Only completed functional Cdc50flippase complexes are able to leave the endoplasmic reticulum and flip lipids in the presence
of ATP.128–131 The exception to this rule is the class 2 P4 ATPase flippase proteins ATP9A
and ATP9B (and Neo1p in yeast)58 which naturally lack Cdc50 proteins.132,133 Hs have three
different Cdc50 proteins, Cdc50a, Cdc50b, and Cdc50c.134 Only Cdc50a and Cdc50b are
associated with P4-type ATPase flippase proteins. Cdc50c was only found in testes and not
found to be associated with P4 ATPase flippases.135 It is perplexing to think that only two
unique β-subunits are associated with the 14 varieties of P4 ATPase flippases in Hs. It is
possible that unique glycosylation of the Cdc50 subunits plays a role in specificity of the βsubunit for each flippase.136
Yeast also has three Cdc50 proteins, Cdc50p, Lem3p, and Crf1p. It was hypothesized
that Cdc50p helps to align ATP molecules in the flippase nucleotide binding domain (N
domain) in the P4 flippase Drs2p. Drs2p is responsible for translocating PS from the lumen to
the cytofacial side of the trans Golgi network (TGN) membranes.137 This alignment step is
likely crucial to facilitate ATP phosphorylation of an aspartate residue in the P domain. The
affinity between the two subunits of the flippase were observed to vary during its catalytic
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cycle, presence of the loaded phospholipid yielded the strongest affinity.138 The other P4
flippases in yeast have also recently been described. Dnf1p, Dnf2p, Dnf3p can all translocate
PS, PE, and PC to varying degrees, but the first two Dnf proteins can bind a variety of other
substrates as well. Neo1 has been implicated in transport of PE and PS.139
An analysis of the C. neoformans genome revealed the existence of four putative P4
type flippases, Apt1p-4p, and only 1 β-subunit Cdc50. Like Neo1p in yeast, its homolog Apt4p
is classified as a P4B flippase. Apt1p and Apt2p are homologous to Dnf1p and Dnf2p and
have broad substrate specificity. Apt3p is the suspected principal PS transporter homolog of
Drs2p.139 Since the MIC of caspofungin against C. neoformans on its own is high, and the
bioavailability of the drug is low, it would be useful to discover a new molecule that could
potentiate the effects of caspofungin, since it is still the current safer alternative.140
Rational design of an AFP
It was surprising that mutations to genes coding for cellular components completely
unrelated to β-D-glucan synthase led to caspofungin susceptibility in Cn. Overall, the goal of
this research was to leverage the knowledge that this mutation led to drug susceptibility. It
was thought that flippase inhibitors could be developed from a region of the Cdc50 loop region
by lipidating a short segment that was thought to participate in the cooperativity of the protein.
Since crystal structures for these fungal flippase proteins do not currently exist, the first
problem was identifying which key segments of interest might be important for activity of the
protein.
An in vivo model in combination with other lab techniques were used by our
collaborators at Rutgers to screen the Cdc50 loop region for target sequences of interest.
Cryptococcal Cdc50 antigens that had significant amount of antibody binding in vitro were
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used as a starting point for the first generation of peptides. Invitrogen generated polyclonal
antibodies based on 15 amino acid sequences derived from the Cdc50 loop region. These
peptides were presented on the surface of mammalian lymphocytes to stimulate the production
of antibodies. The limitations of these antibodies became apparent when deployed against
healthy fungal cells. The antibodies are very large molecules on the order of hundreds of kDa,
they are too big to penetrate the fungal capsule and bind strongly to their target. This research
aimed to address this limitation by examining the effects of lipidated peptide sequences based
on the antigen sequences that were most strongly bound by the antibodies.
Unlike the humimycins studied in Chapter 2 and DAP studied in Chapter 1 that are
NRPs associated with synthetases, the antifungal lipidated peptides synthesized in this work
were based on antibody sequences identified to bind strongly to short segments of the Cdc50
loop region in spheroplast fungal cells. The two sequences identified as sequence 1 (AS15)
and sequence 41 (QY15) were synthesized as N’ C14 lipidated peptides and free N’ peptides
and tested against C. neoformans on their own and mixed with caspofungin in MIC assays
and checkerboard assays. Sequence 41 is unique to the Cryptococcal Cdc50 protein and
sequence 1 is somewhat conserved in Hs Cdc50a. Peptides that proved to be antimicrobial
were further modified and tested iteratively to generate the current lead compound, AW9Ma.141 This process is discussed further below and summarized in Figure 20.

§3.3. Methods
Peptide synthesis
Peptide sequences K5A, K6A, KKAA, (FITC)KW10-Ma were purchased from
Biomatik (ON, Canada). All other sequences were synthesized in-house via microwave
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assisted solid phase peptide synthesis (SPPS) on Wang resin. Standard FMOC/tBu protection
scheme was used. Batches were started typically at the 0.1, 0.2, or 0.3 mmol scale, split for
different modifications, and finished at the 0.05 or 0.1 mmol scale. Successive rounds of
coupling and deprotection reactions were used to synthesize the peptide. The beads in the
reaction chamber were washed with DMF between every reaction to lower any carry over
between deprotection and coupling reactions. HCTU and DIEA were used respectively as the
activator and base in FMOC-amino acid coupling reactions. The deprotection solution was 20
% v/v piperidine in DMF.
FATs were coupled primarily using their respective anhydrides, C2 – C14 in the
presence of DIEA. Palmitic acid C16 was used instead of its corresponding anhydride due to
issues with solubility; in this case HCTU and DIEA were used to couple palmitic acid.
Alexafluor350-succinate ester was used to attach the fluorophore to the lysine side chain of
AK10(AF)-Ma. A cleavage cocktail of TFA, TES, and water was used to liberate the crude
peptide from solid support. Peptides were concentrated to a solid plug at the bottom of a
Falcon tube by removing TFA with a steady stream of N2 gas. Crude peptide was further
isolated by dissolving in 20 – 30 mL 10 % acetic acid in water, freezing in the -80 °C freezer,
and lyophilizing to dry powder. Each reaction and microwave power scheme used are detailed
below, Reaction 7 - Reaction 13, and Table 12 - Table 16 respectively.
Stage
Temp °C
Hold time min
Power watt
1
60
0:07
70
2
70
5:00
35
Table 12. Microwave settings for standard FMOC-amino acid coupling. Arginine was double
coupled.
Stage

Temp °C

Hold time min
45

Power watt

1
50
0:07
50
2
70
5:00
35
Table 13. FMOC-amino acid microwave settings for coupling Glycine, Tryptophan, and for
coupling the first amino acid the first time.
Stage
Temp °C
Hold time min
Power watt
1
40
0:07
40
2
50
5:00
20
Table 14. FMOC-amino acid coupling conditions for histidine. Histidine was double coupled.
𝐷𝑀𝐹
5 𝑚𝑖𝑛𝑢𝑡𝑒𝑠
70°𝐶

𝐵𝑒𝑎𝑑 − 𝑂𝐻 + 3𝐹𝑀𝑂𝐶 − 𝐴𝐴 + 3𝐻𝐶𝑇𝑈 + 6𝐷𝐼𝐸𝐴 →

𝐹𝑀𝑂𝐶 − 𝐴𝐴 − 𝐵𝑒𝑎𝑑

Reaction 7. First amino acid was coupled 4 times to ensure as much of the resin was labeled
as possible. Qualitative ninhydrin tests were not used. Only histidine and arginine were double
coupled.

Stage
Temp °C
Hold time min
1
75
0:01
2
90
1:30
Table 15. Microwave power scheme for FMOC deprotection reaction.
𝑣
1.5
𝐹𝑀𝑂𝐶 − 𝐴𝐴 − 𝐵𝑒𝑎𝑑 + 20% 𝑝𝑖𝑝𝑖𝑟𝑖𝑑𝑖𝑛𝑒 𝑖𝑛 𝐷𝑀𝐹 →
𝑣

90°𝐶
𝑚𝑖𝑛𝑢𝑡𝑒𝑠

Power watt
225
35

𝐵𝑒𝑎𝑑 − 𝐴𝐴 − 𝑁𝐻2

Reaction 8. FMOC deprotection reaction exposing the free amino terminus.

Stage
Temp °C
Hold time min
1
60
0:07
2
70
5:00
Table 16. Microwave power scheme for coupling FATs.
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Power watt
225
35

𝐷𝑀𝐹
5 𝑚𝑖𝑛𝑢𝑡𝑒𝑠
70°𝐶

2𝐵𝑒𝑎𝑑 − 𝑝𝑒𝑝 − 𝑁𝐻2 + 3𝑀𝑦𝑟𝑖𝑠𝑡𝑖𝑐 𝑎𝑛ℎ𝑦𝑑𝑟𝑖𝑑𝑒 + 6𝐷𝐼𝐸𝐴 →

2𝐵𝑒𝑎𝑑 − 𝑝𝑒𝑝 − 𝑀𝑎

Reaction 9. Mystic acid labelling. This FAT was double coupled to ensure maximum labeling.

𝐷𝑀𝐹
5 𝑚𝑖𝑛𝑢𝑡𝑒
70°𝐶

𝐵𝑒𝑎𝑑 − 𝑝𝑒𝑝𝑡𝑖𝑑𝑒 − 𝑁𝐻2 + 𝑃𝑎 + 𝐻𝐶𝑇𝑈 + 3𝐷𝐼𝐸𝐴 →

𝐵𝑒𝑎𝑑 − 𝑝𝑒𝑝 − 𝑃𝑎

Reaction 10. Palmitic acid FAT labelling reaction. This FAT was double coupled, each using
1:1 stoichiometry of fatty acid to peptide. The acid was used instead due to solubility issues
of the anhydride.

2% ℎ𝑦𝑑𝑟𝑎𝑧𝑖𝑛𝑒

→

𝑣
𝑣

𝑖𝑛 𝐷𝑀𝐹
15 𝑚𝑖𝑛𝑢𝑡𝑒𝑠
𝑟𝑜𝑜𝑚 𝑡𝑒𝑚𝑝

Reaction 11. Lysine(DDE) deprotection. This reaction was used to liberate the lysine side
chain amino group for labeling with the fluorophore. This deprotection reaction was carried
out twice prior to proceeding with coupling.
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𝑅𝑜𝑜𝑚 𝑡𝑒𝑚𝑝
𝐷𝑀𝐹
24 ℎ𝑜𝑢𝑟𝑠

+ 𝐴𝐹350 − 𝑠𝑢𝑐𝑐𝑖𝑛𝑎𝑡𝑒 →

Reaction 12. Coupling reaction between alexafluor350 and lysine side chain. Alexafluor350succinate ester was the starting material using for this reaction. This reaction was carried out
at the 0.01 mmol scale.
𝑣
2.5% 𝐻2𝑂, 2.5% 𝑇𝐸𝑆
𝑣
95% 𝑇𝐹𝐴
𝑟𝑜𝑜𝑚 𝑡𝑒𝑚𝑝, 1 ℎ𝑜𝑢𝑟

𝐵𝑒𝑎𝑑 − 𝑝𝑒𝑝𝑡𝑖𝑑𝑒 − 𝐹𝐴𝑇 →

𝑃𝑒𝑝𝑡𝑖𝑑𝑒 − 𝐹𝐴𝑇

Reaction 13. Reaction conditions for the cleavage of crude peptide.

Purification and characterization
The crude peptide was characterized as an off-white to yellow powder. Crude peptides
were purified using a preparatory scale HPLC, and fractions were collected manually. The
resulting fractions were analyzed on the HPLC and ESI-MSD to determine fraction purity and
composition. The resulting fractions that contained the target analyte at a sufficient purity
were mixed and concentrated using a rotary evaporator. The resulting concentrate was
acidified with glacial acetic acid to 10 % acetic acid v/v, frozen in the -80 °C freezer, and
lyophilized to a dry powder. Purified peptides were characterized as white to off-white
powders. The yield, purity, and mass spectra were recorded using an electronic balance,
HPLC, and ESI-MSD respectively for crude and pure products.
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Detailed purification and characterization information can be found in Appendix A.
Mass Spectra, Appendix B. Chromatograms, and Appendix C. Circular Dichroism Spectra.
Chromatograms for all samples synthesized in house were generated using the Shimadzu
Nexera-i 3D plus HPLC-PDA. Mass spectra were recorded on either the HP1100 ESI-MSD,
or the MALDI-TOF at University of Illinois to confirm the molecular identity.

Peptide stock solution
A peptide aliquot of 0.5 – 4 mg was weighed in a sterile Eppendorf tube. The tube was
centrifuged for one minute at 3000 rpm to pack down loose powder to the bottom of the tube.
The peptide was diluted to a concentration of 12.8 mg/mL using DMSO filtered through a 0.2
µm filter.

Passaging fungal cells
Stock fungal cells of C. neoformans wild type and mutant were obtained from the
Public Health Research Institute (PHRI), (Newark, NJ). C. Glabrata stock cells were obtained
from ATCC. All microbiological experiments using fungi were carried out with freshly
passaged live cells. If no recent culture of the microbe was present in the BSL2 fridge, stock
microbes were defrosted from the -80 °C freezer for passaging. An aliquot of 100 μL stock
microbe solution was diluted in 3 mL of YPD in a 10 mL tube. Freshly inoculated tubes were
vortex mixed briefly and then grown in an incubator shaker at 37 °C and 250 rpm. Passages
of C. neoformans were grown for 48 hours before harvesting and passages of C. glabrata were
grown for 24 hours. MIC assays and checkerboard assays required freshly passaged cells be
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subsequently grown as monocultures on SDA plates. SDA plates were incubated at 37 °C for
48 hours for C. neoformans and 24 hours for C. glabrata before harvesting for microdilution
assays.

Quantifying cell concentration using McFarland standard
All microbiology experiments required a cell concentration measurement to correctly
dose 96 well plates with the right number of cells. Comparison between fungal cell suspension
in PBS to 1x McFarland standard was carried out to quantify the concentration of fungal cells.
One-hundred μL aliquot of PBS, McFarland standard, and cell suspension were pipetted in
triplicate into 9 wells of a 96 well plate. The absorbance of each component was recorded at
530 nm using a plate reader. The measurements between replicates were averaged. Then the
average absorbance of the PBS blank was subtracted from the average McFarland standard
and average sample absorbance. Next, the ratio of corrected sample absorbance to corrected
standard absorbance was computed. A product of the ratio and 1 x 107 was computed to yield
the cell concentration in CFU/mL.

MIC assay
The sample prep consisted of prepping microbes, setting up drug dilutions on a 96 well
plate, inoculating the plate with microbes, and incubating the plate. The data acquisition and
interpretation were done simultaneously because the observations were straight forward. It
was noted whether the experimental wells were consistent with either of the controls or not.
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A 100 μL aliquot of RPMI media was charged to each well of a 96 well plate. An
additional 100 μL aliquot of RPMI was charged to the first column. Four μL Peptide-DMSO
stock solution was diluted 50-fold in column 1. The dosed liquid in column 1 was serially
diluted to column 11, transferring 100 μL each time. Monocultured cells were harvested with
an inoculation loop from an SDA plate culture, two-days old for C. neoformans, or one day
old for C. Glabrata, and suspended in 1 mL PBS in an Eppendorf tube. The concentration of
cells was quantified via McFarlain’s standard comparison. Ten mL of a fungal inoculating
solution was prepared in RPMI at 5,000 CFU/mL for C. neoformans, 25,000 CFU/mL for C.
Glabrata. 100 μL fungal inoculant solution was charged to each well on the plate except for
column 11. Column 11 was the negative control, column 12 was the positive control. There
were 500 cell/well for C. neoformans and 2500 cell/well for C. Glabrata.
The inoculated plate was incubated at 37 °C for two days C. neoformans, or one day
C. glabrata. Incubated plates were inspected visually for growth. It was noted if the data point
was consistent with the positive control, negative control, or if it was inconsistent with both
controls. This procedure was consistent with the protocols from the Clinical and Laboratory
Standards Institute (CLSI) handbook on fungal cell work.

Checkerboard assay
This sample prep is nearly identical to the MIC assay, except there are 4 sets of drug
serial dilutions instead of 1. Each well in the 96 well plate was charged with 100 μL RPMI
media, except for wells in column 11. An extra 100 μL RPMI media was charged to the first
column and the 4 μL of the first drug stock solution was diluted 50-fold. An aliquot of 100 μL
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solution was serially diluted by 8 factors of 2 from column 1 to column 8. The extra 100 μL
solution from column 8 was charged to column 11.
Another 100 μL RPMI was charged to the first 10 wells in row one. A 2 μL aliquot of
the second drug stock solution was diluted 100-fold in the first eight wells of row one. A 100
μL aliquot of solution was serially diluted by a factor of two, eight times from row on to row
eight. The extra 100 μL volume from row eight was added to the wells in column 11. A 2 μL
aliquot of each peptide stock solution was diluted 100-fold individually in either column nine
or column ten. A 100 μL aliquot solution from column nine and ten was serially diluted by a
factor of two, eight times from row one to row eight. The extra volume of liquid from row
eight was discarded.
The fungal inoculant was prepared in the same manner as the MIC experiment.
Monocultured fungal cells were harvested with an inoculation loop and suspended in 1 mL
PBS in an Eppendorf tube. The concentration of cells was measured by comparison to
McFarlain’s standard. A 10 mL aliquot of fungal inoculation solution was prepared in RPMI
media at 5,000 CFU/mL. A 100 μL aliquot of the inoculation solution was charged to each
well on the plate except for column eleven. Columns nine and ten were the MIC controls of
the individual drugs alone. Column eleven was the negative control. Column twelve was the
positive control.
The plate was incubated at 37 °C for two days. The plates were inspected visually, and
the results were recorded in a lab notebook. It was noted if the observed growth was consistent
with that of the positive control, the negative control, or neither. FIC index was computed by
summing the ratios of FIC to MIC of both drugs.

52

Hemolysis assay
The sample prep consisted of preparing the blood inoculant from stock RBCs, serially
diluting drugs on a 96 well plate, inoculating and incubating the plate, and preparing the
analysis plate. Data acquisition consisted of recording the absorbance of each well on the
analysis plate. Data processing consisted of averaging, correcting, normalizing, and plotting
the data.
RBCs were obtained from the Interstate Blood bank, (Philadelphia, PA). The first step
was to prepare the blood inoculation solution from stock RBCs. A 1 mL aliquot of stock RBCs
was transferred to two, 15 mL Falcon tubes. Free heme was extracted from the stock RBCs
three times each with two mL PBS, or until the aqueous layer no longer appeared colored after
centrifugating. The RBCs were isolated each time via centrifugation at 1,000 rpm for five
minutes. The concentration of RBCs in a PBS working solution was quantified using a
hemocytometer. An aliquot of the working solution was further diluted in PBS to generate 5
mL of blood inoculating solution at the prescribed cell concentration. Method development
was carried out to determine an appropriate concentration of RBCs in the final experiment.
Cell concentration of blood inoculation solution for AFP hemolysis was 5 x 108 cell/mL.
The second step was to prepare the drug dilution on a 96 well plate. A 50 µL aliquot
PBS was charged each well in an 8x8 grid plus an additional 2x4 grid on the 96 well plate. A
second 50 µL aliquot of PBS was added to the first 8 wells of row 1. A 2 µL aliquot of peptideDMSO stock solution was diluted 50-fold by mixing with the PBS in row 1. Solution in row
1 was serially diluted to row 8, 50 µL per transfer, in total by a factor of 28. The extra 50 µL
from the final row was discarded. A 50 µL aliquot of blood inoculating solution was charged
53

to each row in the 8x8 as well as 2x4 grids. A 2 μL aliquot of a 1 % TritonX solution was
added to one of the rows in the 2x4 grid to act as a positive control. The second row was left
undisturbed as a negative control. The operating conditions were a concentration of 2.5 x 108
cell/mL, volume of 100 µL, and peptide concentration window from 128 µg/mL to 1 µg/mL.
Each drug concentration and control were prepped in quadruplicate (n = 4) on each plate.
The third step was incubation. The inoculated 96 well plate was incubated at 37 °C for
one hour. After incubation, the plate was centrifuged under the previous conditions, to
separate the intact RBCs from the supernatant. The fourth step was to prepare the analysis
plate. While the incubation plate was spinning down, PBS was charged to an 8x8 and 2x4 grid
on a fresh and clean 96 well plate for the spectral scan. The dilution factor of the supernatant
from the spun-down incubation plate to the analysis plate was analyzed during method
development, and a 5-fold dilution factor was chosen for the AFP hemolysis assays. A 20 μL
aliquot of supernatant was transferred to 80 μL PBS. The penultimate step was data
acquisition. The absorbance of the analysis plate was recorded at 410 nm using a plate reader,
the operating volume was 100 µL. Each plate was scanned in triplicate.
The final step was to analyze the data. First, averages and standard deviations between
plate scans were computed. Next, averages and standard deviations between drug
concentration replicates on the plate were computed. The average measurement of the
negative control reading was subtracted from the rest of the data set. The data set was then
normalized to the positive control and multiplied by 100 to yield final values as % hemolysis.
The various data was plotted using Microsoft Excel.
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Confocal microscopy
Sample prep for confocal microscopy consisted of isolating, cleaning, isolating again,
and resuspending freshly grown cells. The cleaned and resuspended cells were diluted 20-fold
and cell concentration was quantified using a McFarland standard comparison. Cells were
aliquoted, volumes adjusted, and stained. Stained cells were isolated, fixed, isolated again,
resuspended in imaging solution, and loaded onto glass slides. Slides were sealed and imaged
on the Olympus Fluoview. Data was processed with Fiji software.
In more detail: Fungal cells were freshly passed twice over the course of four days to
ensure a healthy population of cells for imaging. On the day of the experiment, prior to
processing the live cells, the working drug solution was prepared. A DMSO stock solution of
AK10(alexafluor350)-Ma was diluted 50-fold in PBS to 200 μL and a concentration of 256
μg/mL.
A 1 mL aliquot of freshly passed cells was transferred to an Eppendorf tube. The cells
were isolated using a microcentrifuge and subsequently removing the supernatant with an
autopipette. The samples were spun down for five minutes per spin cycle. Fresh cells were
washed in 1 mL of PBS and incubated at 25 °C, 250 rpm, for five minutes. Washed cells were
isolated and resuspended in 1 mL of PBS. An aliquot of 50 μL cleaned and resuspended cells
were diluted 20-fold to 1 mL in PBS. The cell concentration of the 20-fold dilution was
quantified via comparison to 1x McFarland standard. The measured concentration was used
to solve for the appropriate volumes of diluted cell suspension to transfer 1*106 cells per tube.
After transferring the cells, volumes of each experimental tube were adjusted to 100 μL or
1*107 cells/mL with PBS.
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Subsequently, 100 μL of the drug working solution was diluted two-fold by mixing it
with the cells. The operating parameters for the staining process were a volume of 200 μL,
cell concentration of 5 x 106 cell/mL, and 128 μg/mL peptide. The cells were incubated at 25
°C and 250 rpm for 25 minutes while staining. The stained cells were isolated again on the
microcentrifuge and fixed in 4 % formaldehyde in PBS. The fixing process involved
incubating the cells at 25 °C and 250 rpm for five minutes. The fixed cells were isolated one
last time and resuspended in 100 μL of 1 % formaldehyde in PBS. An aliquot of 5 μL final
cell suspension was transferred to a glass slide and sealed with quick drying liquid acrylates,
nail polish. False colors were applied by FIJI to visualize the resulting image more easily.

Annexin V assay
Sample prep involved isolating cells, washing in PBS, isolating and resuspending the
cells again. The clean resuspended cells were diluted 20-fold for a cell concentration
measurement. Final aliquots of cells were prepared and mixed with the drug working solution
for staining. Stained cells were isolated, fixed, isolated again, and resuspended in the running
liquid and stored on ice until data acquisition. Initial sample injections were used to calibrate
the acquisition parameters for subsequent samples. Data was collected using the MACS Quant
analyzer, Miltenyi Biotec flow cytometer. Data was transferred and processed off-line using
software provided by Miltenyi.
To begin the sample prep, C. neoformans was freshly passaged twice over the course
of four days to ensure a healthy viable population of cells for the experiment. On the day of
the experiment, fresh drug working solutions were prepared just prior to processing the live
cells. The working drug solution was prepared in PBS targeting 400 μL total volume, 20-fold
56

dilution of stock annexin V solution, 2 μg/mL PI and 256 μg/mL peptide. The concentration
of each component in the working solution is twice as high than in the final operating solution.
Separate stock solutions of PI and peptide were 1.0 mg/mL and 12.8 mg/mL in DMSO
respectively. PI stock solution was serially diluted first 10-fold v/v in PBS and then again into
the working drug solution.
The operating parameters for the staining process were volume of 200 μL, cell
concentration of 5 x 106 cell/mL, 40-fold stock annexin V dilution, 1 μg/mL PI and 128 μg/mL
peptide. The fixed cells were isolated one final time and resuspended in 400 μL 1 %
formaldehyde in PBS. Steps not specified here are otherwise consistent with analogous
processing steps described in the confocal microscopy procedure sample prep. See Appendix
F for additional information on sample prep, data acquisition, and data analysis.
§3.4. Results and Discussion
Peptide summary
Table 17 describes each of the AFP sequences synthesized. Group 1 peptides, dubbed
QY15 and QY15-Ma, were 15-AA peptides inspired by “sequence 41” antibody. Group two
peptides consist of N’ FAT scan of the 15 AA peptide inspired by the “sequence 1” antibody.
FAT substitutions include linear saturated fatty acids, C2, C6, C10, C14, and C16, as well as
no FAT. Group 3 peptides consist of truncated sequences inspired by the AS15-Ma peptide.
Each peptide was composed of nine consecutive amino acids followed by N’ labeling with
Ma.
All subsequent groups were based on the AW9-Ma sequence. Group 4 peptides consist
of alanine substituted peptides where the lysine residues were systematically substituted to
determine which one was most important for activity. Group five peptides consist of two
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fluorophore labeled peptides. FITC was conjugated to a C’ terminal lysine side chain of
KW10-Ma. Alexafluor350 was conjugated to the N’ terminal lysine side chain of AK10-Ma.
Group
Short name
Sequence
number
1
QY15
YVDGFPNLREDEHFQ
1
QY15-Ma
Ma-YVDGFPNLREDEHFQ
2
AS15
SESGIAWGGIKKNYA
2
AS15-Ac
Ac-SESGIAWGGIKKNYA
2
AS15-HA
Ha-SESGIAWGGIKKNYA
2
AS15-Da
Da-SESGIAWGGIKKNYA
2
AS15-Ma
. Ma-SESGIAWGGIKKNYA
2
AS15-Pa
Pa-SESGIAWGGIKKNYA
3
AW9-Ma
Ma-WGGIKKNYA
3
KS9-Ma
Ma-SGIAWGGIK
3
GS9-Ma
.
Ma-SESGIAWGG
3
AW9-Pa
..
Pa-WGGIKKNYA
4
A5K
..
Ma-WGGIAKNYA
4
A6K
..
Ma-WGGIKANYA
4
AAKK
..
Ma-WGGIAANYA
5
(FITC)KW10-Ma
Ma-WGGIKKNYAK(FITC)
5
AK10(AF)-Ma
Ma-(Alexafluor350)KWGGIKKNYA
Table 17. Summary of AFP sequences created.

Mol. Wt.
1865.98
2076.34
1580.76
1622.80
1678.91
1733.94
1791.13
1819.18
1246.56
1098.40
1072.27
1274.62
1189.46
1189.46
1132.37
1764.12
1670.00

Peptide masses were confirmed via mass spectrometry. Most samples were analyzed
in-house on the HP1100 ESI-MSD, however some samples were sent to University of Illinois
for analysis on a MALDI-TOF. Observed MS peaks of finished product are compiled in Table
18 and the full spectra are provided in Appendix A. Corresponding m/z of all reported peptide
sequences were observed as either +1, +2, or Na+ adduct.
Yields, purity, and retention times are compiled in Table 19. Chromatograms of
finished products were reported in Appendix B. All target sequences were successfully
synthesized at reasonable yield and purity. Purity is reported from the 220 nm channel
analyzing the peptide bond. GS9-Ma had the lowest yield due to solubility issues limiting the
amount that could be purified on the preparatory scale. The expected retention times increase
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as a function of FAT length of the peptide derivatives of AS15 is observed under reverse phase
conditions.
Short name

Computed m/z
+1

+2

+3

Observed
m/z

Comment

QY15
1866.99
934.0
622.99
932.9
+2
QY15-Ma
1792.13
896.57
598.04
895.5
+2
AS15
1581.77
791.39
527.92
790.4
+2
AS15-Ac
1623.80
812.4
541.93
812.3
+2
AS15-HA
1679.91
840.455
560.63
840.5
+2
AS15-Da
1734
867.97
578.98
869.6
+2
AS15-Ma
1792.13
896.57
598.04
895.5
+2
AS15-Pa
1820.18
910.59
607.39
910.0
+2
AW9-Ma
1247.56
624.28
416.52
1247.7; 624.0
+1, +2
KS9-Ma
1099.40
550.2
367.13
1098.7, 551.0
+1, +2
GS9-Ma*
1073.27
537.135
358.42
1095.6
+1(1Na)
AW9-Pa
1275.62
638.31
425.87
1275.6, 637.8
+1, +2
A5K**
1190.47
595.735
397.49
1187.9
-1
A6K**
1190.47
595.735
397.49
1190.05
+1
AAKK**
1133.37
567.19
378.46
567.1
+2
(FITC)KW10- 1765.12
883.06
589.04
1765.45, 883.05
+1, +2
Ma**
AK10(AF350)- 1669.86
835.93
557.62
1668.4, 568.0
+1, +3(1Na)
Ma*
Table 18. Mass Spec results for AFP samples. * Peptides manufactured in-house, mass spec
analysis by University of Illinois MALDI-TOF. **Peptides produced and analyzed by
Biomatik

59

Short name

Crude
yield %
102.6
89.67
111.5
117.6
95.8
103.3
111.4
97.9
104.1
97.5
98.8
105
-

Crude purity
220 nm
67.2
67.7
56.7
60
50.6
62.9
32.2
70.4
-

Pure yield
%
36.9
64.4
78.4
99.9
54.7
76.2
67.3
59.7
62.3
66.3
34.2
46.5
-

Final purity
220 nm
96.9
80.5
97.6
98
96.3
93.8
95.7
78
85.1
79.0
68.5
85.2
95.3
95.9
95.42
96.4

Retention
time
4.764
7.494
4.479
4.723
5.147
6.251
6.442
7.204
6.75
8.946
11.32
7.654
11.553
13.235
10.898
11.16

QY15
QY15-Ma
AS15
AS15-Ac
AS15-HA
AS15-Da
AS15-Ma
AS15-Pa
AW9-Ma
KS9-Ma
GS9-Ma
AW9-Pa
A5K*
A6K*
AAKK*
(FITC)KW10Ma*
AK10(AF350)109
71.7
87
7.74
Ma**
Table 19. Tabulated yield, purity, and retention times of samples. Reported retention times
are corrected for differences in injection time relative to the start of the run. Time domain
relationship between injection and gradient program remained constant.
–: No data available.
*: Manufactured by Biomatik, data provided by their quality control department; samples
analyzed using an ODS column.
**: Purity reported for 350 nm channel.
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MIC μg/mL
H99
CDC50Δ
QY15
>128
>128
QY15-Ma
>128
128
AS15
>128
128
AS15-Aa
>128
>128
AS15-Ha
>128
>128
AS15-Da
>128
>128
AS15-Ma
>128
8
AS15-Pa
>128
128
AW9-Ma
64
2
AW9-Pa
>128
8
KS9-Ma
>128
>128
GS9-Ma
>128
>128
K5A
>128
>128
K6A
>128
>128
KKAA
>128
>128
Caspofungin
16
4
Table 20. MIC values of AFPs against C. neoformans.
Peptide

Peptide
QY15-Ma
AS15
AS15-Ma
AS15-Pa
AW9-Ma
AW9-Pa
Table 21. FICs

FIC μg/mL
FIC index
H99
ΔCDC50
H99
ΔCDC50
0.5, 8
1, 0.5
0.5 – 1
0.25
(0.5 , 8),
1, 0.5
(0.5-1)
0.25
(64, 16)
(FIC > 1)
0.5, 8
0.25, 0.25
0.5 – 1
0.09
0.5, 8
2, 2
0.5 – 1
0.53
16, 4
0.125, 0.125
0.50
0.09
0.5, 8
2, 1
0.5 – 1
0.75
reported are the AFP concentration followed by caspofungin concentration.

FIC index in computed with equation 1.

Peptide
MIC μg/mL
AS15-Ma
>128
AW9-Ma
>128
AW9-Pa
>128
Caspofungin
0.25
Table 22. MIC values of peptides against C. Glabrata.
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Antimicrobial activity of the peptide was sensitive to FAT length
The first generation of peptides synthesized was QY15, QY15-Ma, AS15, and AS15Ma. The most conspicuous data point from first generation peptides was the MIC of AS15Ma against the Cdc50Δ mutant at 8 μg/mL. While some of the peptides showed a mild additive
effect when mixed with caspofungin, none of the other three peptides inhibited growth of
either strain at such a low concentration independently. AS15-Ma showed enhanced
antifungal activity when mixed with caspofungin, FIC of 0.5 - 1 and 0.1 against the WT and
mutant respectively. A precise FIC index could not be reported for some experiments since
the original peptide MIC was greater than the concentration window analyzed.
MIC and FIC data is summarized in Table 20 and Table 21 respectively. Group 2
peptides consisted of a FAT scan of the AS15-Ma molecule. The FAT used were C2, C6, C10,
C14, C16. The only peptide capable of inhibiting fungal growth in vitro was AS15-Ma.
Growth in the wells treated with high concentrations of unlabeled peptide AS15 had enhanced
quantity of confluent growth than the cells grown in the positive-growth control condition
suggesting the unlabeled peptide may have acted as a nutrient supplement.

Sequence truncation improved antimicrobial activity
Group 3 peptides were truncated sequences based on AS15-Ma. From a structural
perspective, it was desirable to identify which region of the AS15-Ma peptide was important
for activity. From a biophysics perspective, a tryptophan residue in all the sequences was
retained due to the number of useful biophysical experiments that benefit from its presence.142–
144

From a rational design perspective, it was desired to begin examining the importance of

the lysine since it is well known to be an important component of AMPs that contribute to
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their antimicrobial activity.145,146 GS9-Ma lacked lysine residues entirely. KS9-Ma retained
only one lysine residue. AW9-Ma retained both lysine residues.
The only peptide in this group to prove effective was the AW9-Ma peptide. It was
more potent than the parent molecule since it was able to inhibit the growth of the WT C.
neoformans at 64 μg/mL. MIC of caspofungin was reduced from 16 μg/mL to 4 μg/mL in the
presence of 16 μg/mL AW9-Ma, resulting in an FIC index of 0.5, indicating a strong additive
effect. This result shows that caspofungin activity is enhanced in the presence of AW9-Ma to
the same extent as the mutation resulting in the removal of the Cdc50 region entirely as seen
in Cdc50Δ. Even the presence of a small amount of peptide, (1/2) μg/mL was able to sensitize
C. neoformans to the effects of caspofungin and reduce the MIC from 16 μg/mL to 8 μg/mL.

Lysine is a key component for activity
MIC results of group 3 and 4 peptides showed that both lysine residues were required
for antimicrobial activity of the peptide. Group 4 peptides were based on the AW9-Ma
sequence and consisted of lysine to alanine substitutions. These substitutions were reminiscent
of the alanine scan, a chemical biology approach to identifying binding hotspots.147 K5A had
the first lysine substituted, K6A had the second lysine substituted, and KKAA had both lysine
residues substituted. Removal of either or both lysine residues abrogated their antimicrobial
activity. None of the group 4 peptides were effective at inhibiting the growth of C. neoformans
on their own. Annexin assay results of group 4 peptides showed that substituting the lysine
with alanine in the 5th amino acid position reduced the target inhibition significantly more
than substituting the lysine in the 6th amino acid position, this result is discussed more in the
next section.
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AW9-Ma is a potent flippase inhibitor
Annexin V assays (Appendix F) were used to determine the potency of the peptides as
flippase inhibitors. The signal intensity is directly proportional to the flippase inhibition in
this experiment. The gating strategy rejected nonviable cells with the incorrect size and
morphology from the population used for final analysis. The gating strategy is discussed at
length in Appendix F. Figure 13 and Figure 14 compare the percentage of cells with the correct
morphology that are positive for annexin-V and negative for PI between various conditions.
Figure 13 summarizes the data from all the peptides tested at 128 μg/mL and Figure 14
summarizes the data from the AW9-Ma peptide at different concentrations.
The AW9-Ma peptide was shown to be the most potent inhibitor. It was found that
68.8 % ± 2.1 % cells with the correct morphology were positive for Annexin V and negative
for PI. Most interestingly, this experiment revealed that the presence of both lysine residues
in the AW9-Ma peptides are vital for flippase inhibition, however the lysine in the 5th amino
acid position is more important because far less inhibition was observed when the 5th
compared to the 6th residue, 9.5 % ± 0.6 % versus 19.4 % ± 1.6 % respectively. No significant
difference between the background measurement and the measurement made with the doubly
alanine substituted peptide was detected.
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Figure 13. This graph depicts % cells with the correct morphology that are also annexin
positive and PI negative as a function of which peptide was tested at 128 µg/mL. Error bars
represent ±1 standard deviation.

Figure 14. This graph depicts % cells treated with AW9-Ma that have the correct morphology,
annexin positive, and PI negative as a function of concentration.
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Peptide localizes on the cell surface

Figure 15. Confocal microscope image of Wt Cn cells stained with AK10(AF)-Ma. Image
processing done by FIJI-ImageJ. A false color was applied to visualize the peptide localizing
on the membrane more easily.

AW9-Ma is somewhat hemolytic
Method development of the hemolysis assay was carried out because the protocols
previously reported in the literature are a poor model for physiological conditions due to the
extremely dilute RBCs, 7.7 x 106 cell/mL.148 Physiological blood has an approximate RBC
concentration of 5 x 109 cell/mL.149 Carrying out a hemolysis experiment at physiological
concentration of blood is not feasible due to the relatively high viscosity and surface tension
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of such a concentrated solution of RBCs. The pipetting and transfers would become inefficient, so a significant amount of error would propagate. A diluted solution of RBCs is
required for maximum efficiency of transferring and mixing materials without losing RBCs
in the process.
Transfer volumes of the supernatant were varied to ensure that the final hemolysis
results were always within the linear response region of the detector. Results must be in the
linear response region of the detector for the method to be considered for validation. The
greater the transfer volume, the more total signal could be achieved. Results of the method
development are shown in Figure 16.
The greater the concentration of RBCs used, the steeper the respective best fit line
produced by correlating the signal intensity with different transfer volumes. The steeper the
response curve, the greater the sensitivity of the experiment. The tradeoff for increased
sensitivity is the possibility for increased noise as well. This trend is accurately reflected in
Figure 16 where the data points have increasing uncertainty associated with them the higher
in RBC concentration the experiment was conducted at. Based on the considerations of
physiological representation, uncertainty, and sensitivity previously described, final operating
conditions were chosen for the AFP hemolysis experiment.
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Figure 16. Hemolysis method development results. These data were collected by analyzing
positive control wells at different operating RBC concentrations and transferring different
volumes of supernatant from the incubation plate to the analysis plate. Each best fit line
describes the relationship between different transfer volumes for the same concentration of
RBCs. The concentrations reported represent that of the blood inoculation solution, the
operating concentration is one-half that amount due to the 2-fold dilution at the end of sample
prep. Since all the results were baseline corrected with the negative control, the best fit lines
produced using Excel were force fit through the plot origin (0,0).
The AFP hemolysis results are provided in Figure 17. The samples were mostly not
hemolytic, except for AW9-Ma, and one concentration of caspofungin. The hemolysis
produced because of exposure to AW9-Ma increased noticeably past a certain threshold
concentration required to separate the signal from the background.
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Figure 17. AFP hemolysis results. Each data point was prepared in quadruplicate and scanned
in triplicate at 410 nm. Operating volume for incubation and analysis was 100 μL, operating
concentration of RBCs was 2.5 x 108 cell/mL. Error bars are ± 1 SD. Data is normalized to
positive control that completely lysis all the RBCs.
Asymmetric PS distribution in RBCs contributes positively towards the correct
cellular morphology due to their interactions with the cytoskeletal network. It is not surprising
that a molecule responsible for inhibiting a key process contributing to cellular integrity would
cause damage to a cell or even cell lysis.150 The observed hemolytic activity does not preclude
these AFPs from potential further in vivo, or clinical application because at the concentration
required to potentiate the effects of caspofungin, there is a small amount of hemolysis.
Furthermore, if the hemolytic activity of the peptide is a problem, it is conceivable that this
issue could be prevented if the peptide is formulated with other topical antifungal drugs to
treat cutaneous presentations of C. neoformans.100,102 AW9-Ma sets the hemolytic bar for
modified sequences that are synthesized in the future and are hits for antifungal activity.
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RBC as homologous model for activity
A deeper understanding from a structural and mechanistic perspective was sought by
analyzing what key interactions might be responsible for activity of the drug. The closest
fungal flippase structure that the author could find at the time in the protein databank was the
putative endosomal flippase associated with the TGN, Drs2p-Cdc50p in yeast
(Saccharomyces cerevisiae).151–153 A rigorous in silico investigation of flippase structure, loop
region binding, and peptide-protein docking was just out of reach of the capabilities available
to the researcher at the time, so alternative models were sought to gain deeper insights. The
most conspicuous place to look for a solution was in the RBCs since they are very well
characterized in the literature, and the hemolytic activity of AW9-Ma was noted. Hs RBCs
contain a class 6 P4 ATPase flippase known as ATP11C-Cdc50a.154 This protein maintains
the asymmetric distribution of PS in erythrocytes.155 Sequence alignment was used to match
the β-subunits of Hs ATP11C and Cn P4-ATPase, Figure 18. Protein databank (.PDB) files
of ATP11C Cryo-EM structures in several different conformations were obtained from the
PDB website.156,157 Polar contacts less than 5Å between the α and β-subunit homologs of
AS15 and QY15 were isolated using Pymol software. Changes in polar contact distances
between key α and β-subunit regions in different structural confirmations were noted.
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Figure 18. Sequence alignment used to analyze the ATP11C-Cdc50a structures in Pymol.
This alignment was provided by our collaborators at Rutgers University.141
It was discovered that one of the hydrophobic tails of PS accumulates within 14Å of
the AS15 sequence homolog in Hs ATP11C- Cdc50a structure 7BSU, Figure 19.156 The
canonical binding model of flippase activity proposes that a hydrophobic pocket is formed by
several M-domain transmembrane helices facilitating the spatial translation of the fatty acid
tail of PS in the flippase between membrane faces.58 Taken together, a possible explanation
for the peptide activity was that the peptide portion bound to an analogous spot of the αsubunit where its homolog would normally bind and the myristic acid was the correct length
to span the distance from the peptide binding region to the hydrophobic channel. This
blockage prevented the phospholipid tail from utilizing the hydrophobic channel to slide back
to the other side of the bilayer. This new model of activity contrasts somewhat to the original
notion that the lipid tail locked the protein in a high energy configuration, preventing it from
completing its cyclic activity. The original model was consistent with the observation that
flippase affinity of the β-subunit is at its greatest when PS is bound to Drs2.134,138 The original
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idea was more consistent with the peripheral pathway model also known as a credit card model
where the hydrophilic head group is the only component to bind to the flippase leaving the
FAT to reside in the hydrophobic milieux of the membrane bilayer during translocation.58,158

Figure 19. The fatty acid component of PS (blue) accumulates on the interfacial region of the
α-subunit (green) within 14Å of the AS15 region analog in Hs RBC ATP11C-Cdc50a
(purple), (PDB 7BSU) Image prepared with Pymol.141

Drug resistance is correlated with flippase activity
The exact mechanism linking flippase activity to caspofungin susceptibility is still a
topic for investigation. The Cn Cdc50Δ strain, only missing the β-subunit of the fungal P4flippase was susceptible to caspofungin with a MIC of 4 μg/mL. A very specific lipidated
peptide originating from the Cdc50 sequence could inhibit the Wt Cn with a MIC of 64 μg/mL,
and potentiate the effects of caspofungin with an FIC index of 0.5. Subsequent work by our
collaborators Cao et al. 2019, Rutgers University reported mutants of Cdc50Δ dubbed M1 and
M2 were desensitized to the effects of caspofungin.159 Among the variations in M1 and M2
genomes only 8 changes to amino acid residues were expressed. They tested each of the
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mutations individually and showed deletion of CNAG_01704 coding for CMR1 had the most
potent effect. The double mutant dubbed Cdc50Δcrm1Δ was considered resistant to
caspofungin. Removal of the CMR1 gene had no effect on the WT strain. In almost every
example reported where calcium concentration was an independent variable, the MIC of
caspofungin against the various strains had a direct positive correlation. The presence of
calcium makes the fungus more resistant to caspofungin.
Several possible additional explanations linking Cdc50 to caspofungin resistance are
discussed. Inhibiting the flippase facilitates accumulation of PS on the outer membrane
surface leading to membrane depolarization and the enhancement of the caspofungin
membrane partitioning.141 Membrane partitioning is the first step of caspofungin crossing the
membrane to get to its target. It makes sense that this partitioning process could be enhanced
by a higher-than normal presence of a negatively charged substrate, PS, attracting the
positively charged caspofungin to the membrane surface.
Another possible model to explain the mechanism was that the flippase itself was
directly acting as the exclusionary mechanism and transporting the caspofungin out of the cell.
In this case, the flippase cotransports caspofungin and the phospholipid. Characteristic of an
antiporter, the substrates are transported in opposite directions. Additionally, It is possible that
the Cdc50 loop region acts as a sensor, stimulating the cellular stress response and flippase
activity in the presence of caspofungin. This final idea proposed is supported by the
observation that removal of Crm1 from Cdc50Δ abrogates the mutant strain susceptibility to
caspofungin with a MIC of 16 μg/mL. Additional experiments would be required to test
various aspects and consequences of each model.
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Novel drug discovery pipeline
This novel drug discovery pipeline can be summarized as a 3-step process. The first
step is to identify protein targets responsible for drug resistance. The second step combines a
biological model and a screening process to identify lead synthetic substrate target molecules
to be made in the lab and tested. The third step is to iteratively generate, and test peptides
based on the substrates identified. Each iterative generation of peptide examines the effect of
a rational modification to the substrate on the inhibitory effects produced.
Since the resistance mechanism of C. neoformans against caspofungin was not well
understood at the time, first, genetic mutants were screened to find a susceptible cell line to
the antibiotic caspofungin. Dr. Xue's lab found the susceptible mutant strain was missing
genes coding for the Cdc50 protein. Cdc50 is the β-subunit of a P4-ATPase flippase, a
membrane protein that translocates PS. An animal model was used to develop antibodies
against antigen sequences that were 15 amino acid segments of Cdc50. In vitro antibody
binding assays against the target in spheroplast fungal cells confirmed which antigens
generated the most potent antibody. There were severe limitations to the true in vivo
applicability of these antibodies, but the story didn't end there.
Lipidated peptides were made from the original 15 amino acid sequence that generated
the antibodies. The idea here was to use an animal model in conjunction with an in vitro screen
as a real-world selection tool to reduce the number of possible starting points for a rationally
designed AMP targeting a specific protein. In vitro testing of the peptides showed some
antimicrobial activity from one of the lipidated peptides on its own. The same peptide was
able to potentiate the effects of caspofungin and a subsequent generation of this peptide
showed enhanced antimicrobial activity. The current limitations of the peptide are that they
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seem to only target a specific fungal flippase in C. neoformans and have potential negative
interactions with a flippase in Hs RBCs. Figure 20 summarizes the drug discovery pipeline
described above. Several questions remain after completing this work: What other membrane
proteins are associated with drug resistance? Can this drug discovery process be leveraged to
discover other AMPs or membrane associated resistance inhibitors? What subsequent rational
modifications can be made to AW9-Ma to further increase the in vivo applicability?

Figure 20. Drug discovery pipeline dubbed antigen binding screen for rationally designed
antimicrobial peptides (ABSRD AMPs). * = Dr. Xue’s lab, Rutgers University. ** =
Invitrogen. *** = doctoral work done by Robert Tancer at Seton Hall University.
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Chapter 4. Flippase Inhibitors as Antimicrobial Agents
§4.1 Lipid II flippase inhibitor
Future studies
An interesting biophysics project would be to synthesize a fluorescently labeled
humimycin peptide and analyze the stained bacteria using a high-power confocal microscope.
This would confirm the idea that this peptide accumulates on the surface.
Additional DLS studies should be carried out in the future to better understand the
characteristics of the nanoparticles formed by the humimycins. According to the manufacturer
of the instrument the presence of ions like Na+ and Cl- can affect the measured diameter.
Systematically remeasuring the particle sizes with humimycins diluted in carefully control
buffer solution with an approximate physiological ionic strength would provide data relevant
to future in vivo use. Nanoparticle drug formulations are still at the cutting edge of medical
science and not all the downstream physiological impacts are well understood yet. Since these
are newly characterized drugs that form nanoparticles, it would be a good idea to achieve a
better understanding of their thermodynamics and kinetics. For a starter it would be good to
know what the critical micelle concentration (CMC) is. Another related question is the longterm stability of the nanoparticles in solution? This question can be answered with a
flocculation study, that is examining the nanoparticle morphology as a function of the length
of time aged in water, over minutes, hours, and days using DLS.
The humimycin nanoparticles could be employed as a delivery vehicle for other
hydrophobic drugs. FIC assays carried out by the original authors already showed that there
is some synergy when mixing humimycin in formulation with other antibiotics that also target
the peptidoglycan biosynthesis pathway like β-lactam antibiotics.91 There is a possibility for
76

enhanced synergy beyond that previously observed if the β-lactam antibiotic is specially
loaded into the hydrophobic center of a humimycin nanoparticle. Using humimycin based
nanoparticles as a delivery vehicle for other compounds is made tractable by the preservation
of antimicrobial activity with the tremendous cost reduction of producing the dehydroxy
version of the drug (5B). Furthermore, lipid nanoparticle (LNP) formulations are in the
zeitgeist due to the widespread use of novel vaccine technology to reduce the severity of
infection with COVID19. The key advancement in this generation of vaccines not previously
seen is LNP encapsulated m-RNA delivers a message to the ribosome to produce a viral
antigen that stimulates an immune response. Some reports suggest that the safety of the
nanoparticles is closely related to their size. Serendipitously, the size of the humimycin
nanoparticles are just within the size considered safe.160–162
Conclusions
The discovery of humimycin was a promising step forward in the pursuit of new
antibiotic molecules that can help medical professionals fight drug resistant microbes like
MRSA. Results generated in this work can guide our understanding of the pharmacological
impacts of administering humimycin in vivo. The nanoparticles formed in solution provide a
potential mechanism for synergy. It is conceivable that the nanoparticles can be further
optimized and used synergistically as a delivery vehicle for other hydrophobic antibiotics.
Such a development is made feasible due to reducing the production cost of a peptide while
maintaining its antimicrobial activity.
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§4.2 Cryptococcal P4 flippase inhibitor
Exploring the design space of the Cryptococcal AFP, AW9-Ma
The design space of these AFPs have only begun to be explored. Many different
sequence modifications and sequence scans can be carried out to check structure-activity
relationship (SAR) and further elucidate the hot-spot binding. i) Alanine scan: This process
began with the alanine substitutions for lysine in K5A, K6A, and KKAA. The remaining nonlysine and non-alanine amino acids can still be mutated to see which ones are vital for activity.
ii) Deletion scan: Synthesize new sequences, each missing a single amino acid residue from
AW9-Ma. This will help to answer the question as to whether AW9-Ma is the minimum
sequence with potential activity. iii) Epimerization scan: individually replace each stereogenic
amino acid with its non-proteogenic stereoisomer. A study by Oren and Shai, 1997, found that
a single D-amino acid substitution in melittin led to an AMP that retained antimicrobial
activity while eliminating hemolytic activity.163 Other work has shown that substituting lysine
with ornithine can increase bioavailability and stability of a MAP.164 Such results supports the
hypothesis that additional rational peptide design modifications can further increase the
potency of the peptide and tune the specificity of the towards fungi and away from RBCs,
further increasing its in vivo applicability. If these sequence scans lead to a non-hemolytic
AFP with greater activity that potentiates caspofungin and other antifungal drugs at least as
well as AW9-Ma, that candidate will be the best option to begin the next level of in vivo
testing, a murine model.
Group
number
6.1
6.2
6.3*
6.4*

Comment

Sequence

Alanine scan
Alanine scan
Alanine scan
Alanine scan

Ma-WGGIKKNAA
Ma-WGGIKKAYA
Ma-WGGIKANYA
Ma-WGGIAKNYA
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Mol.
Wt.
1154.5
1203.5
1189.5
1189.5

6.5
6.6
6.7
6.8

Alanine scan
Alanine scan
Alanine scan
Alanine scan

Ma-WGGAKKNYA
Ma-WGAIKKNYA
Ma-WAGIKKNYA
Ma-AGGIKKNYA

1204.5
1259.8
1259.8
1131.4

7.1
7.2
7.3
7.4
7.5
7.6
7.7

Deletion scan
Deletion scan
Deletion scan
Deletion scan
Deletion scan
Deletion scan
Deletion scan

Ma-WGGIKKNY_
Ma-WGGIKKN_A
Ma-WGGIKK_YA
Ma-WGGIK_NYA
Ma-WGG_KKNYA
Ma-WG_IKKNYA
Ma-_GGIKKNYA

1175.5
1083.4
1132.5
1118.4
1133.4
1189.5
1060.4

8.1
8.2
8.3
8.4
8.5
8.6
8.7

Epimerization
Epimerization
Epimerization
Epimerization
Epimerization
Epimerization
Epimerization

Ma-WGGIKKNYa
Ma-WGGIKKNyA
Ma-WGGIKKnYA
Ma-WGGIKkNYA
Ma-WGGIkKNYA
Ma-WGGiKKNYA
Ma-wGGIKKNYA

1246.6
1246.6
1246.6
1246.6
1246.6
1246.6
1246.6

9.1
9.2
9.3
9.4**
9.5**
9.6**

Aromatics
Aromatics
Aromatics
Ornithine
Ornithine
Ornithine

Ma-WGGIKKNWA
Ma-YGGIKKNYA
Ma-YGGIKKNWA
Ma-WGGIKONYA
Ma-WGGIOKNYA
Ma-WGGIOONYA

1269.6
1223.5
1246.6
1232.5
1232.5
1218.5

10.1
10.2
10.3
10.4
10.5
10.6

Hydrophobic
Hydrophobic
Hydrophobic
Hydrophobic
Hydrophobic
Hydrophobic

Ma-WGGAKKNYI
Ma-WGGLKKNYA
Ma-WGGVKKNYA
Ma-WGGIKKNYV
Ma-WGGIKKNYL
Ma-WGGIKKNYI

1246.6
1246.6
1231.7
1274.6
1288.6
1288.6

11.1
Acid/base
Ma-WGGIEKNYA
1247.5
11.2
Acid/base
Ma-WGGIKENYA
1247.5
11.3
Acid/base
Ma-WGGIEENYA
1248.4
Table 23. Investigation of structure-function relationship through sequence modification. * =
6.3 and 6.4 were K5A and K6A respectively. ** = Ornithine substitution for Lysine, K6O,
K5O, KKOO respectively.
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Optimizing the annexin assay
Though the process was refined somewhat, aspects of the annexin V assay could still
be optimized and other parameters explored. In the literature the staining buffer contained
other components including salt (NaCl) and calcium [CaCl2, or CaCO3]. For the sake of
simplifying the sample prep, these components were omitted here. Several papers have
elucidated a relationship between calcium homeostasis, the Cdc50 protein, and caspofungin
resistance in Cn.124–126,159,165 Furthermore, some scramblases are activated by calcium and
could increase the PS exposure of the exofacial leaflet if it is added. It would be interesting to
see what effects modification to osmotic pressure and calcium concentration have on the
morphology, state of the various cell populations, and PS distribution. Higher cell counts, less
osmotic lysis, population morphology changes and increased signal intensities are expected
to occur for changing those parameters.
It would also be interesting to see the effects of using cells in log phase instead of lag
phase, that is after 24 hours of growing the second fresh passage instead of 48 hours. This
experiment would reveal if flippase activity and PS distribution are cellular aspects of fungi
that have characteristic changes as a function of population density in C. neoformans. For
example, changes in the thickness of the fungal capsule as a function of population density
have previously been reported.
Time resolved flow cytometry can reveal the inhibition kinetics.39,166–168 The
independent variable different between experimental groups would be the length of time
samples are incubated during the staining process. Ideally groups would consist of 15-minute
incubation increments of up to 60 minutes. A group with no stains would be a background
control.
80

AFP Cryptococcal resistance screen
Serial passage experiments of Cn in the presence of sub-lethal concentrations of the
peptide AW9-Ma, or combination of peptide and caspofungin can result in mutations that lead
to resistance. It would be interesting to identify what specific mutations lead to resistance of
Cn to the current lead AFP AW9-Ma. It is possible the changes that occur that lead to
resistance can also lead to insight into the specific mechanism of activity if resistance is due
to changes in the target itself like SNPs, or over-expression.
Elucidating the mechanism of activity
In silico results analyzing RBC flippases suggest AW9-Ma interacts primarily with
ATP11C-Cdc50a in Hs. The precise protein target of AW9-Ma in Cn still needs to be
confirmed experimentally, but it is most likely one of the 4 P4 flippases Apt1p-4p. While cocrystallizing the membrane protein with the peptide bound would be the highest level of
evidence, it is also the most difficult way to prove this point because it is exceedingly
challenging to crystalize membrane proteins.169 Other more reasonable approaches would be
to consider: i) Homologous expression (overexpression) of each flippase, one at a time in Cn.
If resistance occurs due to overexpression of one flippase then it is likely that flippase is the
drug target. Some microbes can become resistant because of over-expression of the target
since it takes longer to saturate binding pockets, and it gives the microbe more time to degrade
the drug before succumbing to its effects. ii) Knock out each of the P4 flippases one at a time
to first observe if any of them are required for basal cell viability, then to test the MIC of
AW9-Ma against each of the viable knock out mutants and observe if any are resistant to the
peptide. The knockout mutant lacking susceptibility to the peptide could be interpreted as
resulting from the removal of the drug’s target. iii) There are a couple different ways to carry
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out heterologous expression. The first is to express Cn flippase of the putative target in a
resistant microbe and look for susceptible transgenic mutants. The second is to express
functionally heterologous flippases from other species in Cn to find a resistant transgenic
mutant that is no longer susceptible. So far, the mechanism of activity was proven to be
specific to Cn and Hs RBCs. Since C. glabrata is resistant to AW9-Ma, it is a good candidate
organism for heterologous expression of the equivalent version of the flippase after having
knocked out the native flippase its replacing.
Characterization of the P4 flippases in Cn is lacking. More data about the fundamentals
of these proteins in Cn is needed to understand their behavior and fully leverage them as
antimicrobial targets. Preliminary data from heterologous expression suggests that Apt1p
cannot leave the ER and form a functional lipid flipping unit without the Cdc50 β-subunit.128–
131

Analogous work in mammals lead to the same result. Flippases will not leave the ER and

migrate to the cell membrane to flip lipids without their Cdc50 β-subunit.58 It was also
predicted that Apt4p is the only Cn flippase likely to not require the Cdc50 β-subunit. Taken
together, these observations raise the following questions: i) Do Apt2p and 3p require the
Cdc50 β-subunit to leave the ER and form functional lipid flipping proteins? ii) Are Apt1p,
2p, and 3p obligate P4A flippases or can they functionally operate as P4B flippases in the
absence of a Cdc50 subunit?170 iii) If Apt1-3p are obligate P4A flippases, is Apt4p the only
functioning flippase in Cdc50Δ? It is tempting to claim Apt3p is the protein target of AW9Ma in Cn since it is the putative PS flippase, however currently there is not enough evidence
to support such a claim.139
It would be interesting to test the hemolytic activity of K5A, K6A, and KKAA. If the
hemolytic activity of these sequences follows the same trend they exhibited in the annexin
82

assay, it would demonstrate that PS accumulation and flippase inhibition are intimately linked
to membrane stability and cell viability of RBCs. Afterall, PS signaling does play a role in
apoptosis and blood coagulation in mammals. Subsequent peptide modifications would need
to tune its specificity for the fungal flippase and reduce its binding to ATP11C.
Structural based rational design of P4 flippase inhibitors
The author’s last thought on a potential future avenue of investigation related to this
work is a general structural approach towards future development of lipid flippase inhibitors,
specifically P4 flippases that require the Cdc50 β-subunit, P4A flippases. A recurring
observation between different P4A flippase structures on Pymol was that there are α-helices
of the β-subunit that are structurally homologous to the “sequence 1” region of Cn. These αhelices have different primary sequences however the α-helices are conspicuously located
atop the interfacial hydrophobic channel. It is possible different flippase inhibitors and AMPs
or AFPs can be constructed based on the structural rational that a peptide mimicking these αhelices might bind in the correct location of the α-subunit and insert its hydrophobic FAT into
the hydrophobic channel, blocking flippase activity. Since the primary sequences vary to the
degrees that they do, it is likely these flippase inhibitors would be specific to their target or
species of origin. This process would only work for P4A flippases with known structures. In
the author’s opinion it is somewhat of a coincidence that AW9-Ma only had specific fungal
activity against Cn, but also hemolytic activity against RBCs since the peptide should be
specific to its target.
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Conclusions
Drug resistance has been linked to flippase activity in a rapidly growing number of
drug resistant microbes. For the case reported in this chapter, inhibiting the P 4-type ATPase
flippase with a lipidated segment of the Cdc50 accessory protein potentiates the effects of
caspofungin to the same extent as removing the Cdc50 protein entirely in C. neoformans. This
peptide was shown to be a potent inhibitor leading to significant accumulation of PS on the
outer membrane surface. The flippases are prime drug target candidates worth exploring since
they contribute to the cellular stress response system, are under-utilized targets.
§4.3. Flippase inhibitors
The lipid flippases in pathogenic and drug resistant microbes are a prime target for
antimicrobial drugs. This underexploited target is not well characterized in most organisms
and requires further study. The flippases help maintain asymmetrical concentrations of certain
lipids across the two faces of the membrane. Along with the other lipid transferases, the
floppases, and scramblases, the flippases contribute to the cell stress response by maintaining
membrane homeostasis. The cell can change the composition of the membrane in an attempt
to adapt to stressful environmental conditions or stimuli. Continuing to develop foundational
scientific knowledge on the structure and function of the flippases will increase the ability to
design new compounds that inhibit them. Flippase inhibition is a novel strategy to potentiate
the effects of drugs currently available on the market today.
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Appendix A. Mass Spectra
Background
Mass spectrometry (MS) is a technique used to help identify the composition of a
sample. This instrument has four main components, the inlet, the ion source, the mass
analyzer, and the detector. The inlet introduces the sample to the instrument and is typically
connected to the outlet of an HPLC or syringe for direct injection. The ion source provides
energy to the sample to help ionize the analytes. Typical ion sources are electrospray
ionization (ESI), electron impact (EI), and matrix assisted laser desorption ionization
(MALDI). The ion source dictates types of and extent of ionization. Soft ion sources will only
form the parent ion, while other ionization techniques fragment the analyte into smaller pieces.
The mass analyzer separates the various ions perpendicular to the principal axis of motion
based on their mass to charge ratio (m/z) due to the interaction of the ion with a magnetic
field. Mass analyzers include quadrupole magnets, magnetic sector, and time of flight (TOF).
The detector generates signal based on distance the ion migrated in the mass analyzer, and
amount of analyte hitting the detector. Typically, the detector is a photomultiplier tube (PMT).
The distance traveled by an ion is inversely proportion to its m/z. Smaller m/z ratios cause an
ion to travel further. Two MS techniques were utilized. The in-house instrument was the
HP1100 ESI-single quad-MSD, and some samples were sent to the University of Illinois mass
spectrometry lab for analysis on a MALDI-TOF.
Samples
All humimycin samples were analyzed at University of Illinois mass spectrometry lab on a
MALDI-TOF. Of the AFP samples, only GS9-Ma, and AK10(alexafluor350)-Ma were
analyzed at University of Illinois on a MALDI-TOF. (FITC)KW10-Ma, K5A, K6A, and
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KKAA peptides were analyzed by the quality control department of Biomatik custom peptide
synthesis. All other samples were analyzed in-house using the HP1100 ESI-MS single quad.
The following summarizes the key instrument parameters used. See analytical HPLC section
Background
High pressure liquid chromatography (HPLC) is a highly advanced form of
chromatography that facilitates the separation of complex liquid mixtures. The separation of
mixture components is caused by differential attraction between the analytes, stationary phase,
and mobile phase. The instrument has four main components, mobile phase, the pump, the
stationary phase, and the detector. In combination with the many solvents available, the
different stationary phases can affect almost any kind of separation. C18 or octadecyl silane
(ODS) columns can be used for reverse phase separation and bare silica columns can be used
for normal phase separations. HPLC is compatible with many different detectors. Most
commonly, detectors are devices like photodiode array (PDA), dual wavelength detector, or
refractive index (RI). The capabilities of HPLC are multiplied when it is coupled with several
different detectors like UV-Vis and mass spectrometer. In the context of this work, HPLC was
used for two specific purposes. Preparative HPLC was used to purify large quantities of
peptide on the scale of hundreds of mg. Analytical HPLC was used to analyze the purity of
crude, in-process, and final peptides. Analytical separations were on the scale of 10 μg.
§B1 for sample prep information.
Instrument configuration of HP1100
Positive mode Ionization, ESI Ion sources, Line-A composed of H2O +0.1 % FA, lineB composed of MeOH + 0.1 % FA. Mobile phase was 90 %B isocratic, flow rate of 0.5
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mL/min. Injection volume was 1-10 μL. This instrument was setup for direct injection, no
column was used. Runs were two minutes long.
§A1. Humimycins

Figure A1. MALDI-TOF analysis of peptide 5A
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Figure A2. MALDI-TOF analysis of peptide 5B

Figure A3. MALDI-TOF analysis of peptide 5C
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Figure A4. MALDI-TOF analysis of peptide 6A

Figure A5. MALDI-TOF analysis of peptide 6B
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Figure A6. MALDI-TOF analysis of peptide 6C

Figure A7. MALDI-TOF analysis of peptide 6D
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Figure A8. MALDI-TOF analysis of peptide 7A
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§A2. Antifungal peptide

Figure A9. HP1100, positive mode, ESI-MS analysis of peptide QY15

Figure A10. HP1100, positive mode, ESI-MS analysis of peptide QY15-Ma
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Figure A11. HP1100, positive mode, ESI-MS analysis of peptide AS15

Figure A12. HP1100, positive mode, ESI-MS analysis of peptide AS15-Ac
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Figure A13. HP1100, positive mode, ESI-MS analysis of peptide AS15-Ha

Figure A14. HP1100, positive mode, ESI-MS analysis of peptide AS15-Da
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Figure A15. HP1100, positive mode, ESI-MS analysis of peptide AS15-Ma

Figure A16. HP1100, positive mode, ESI-MS analysis of peptide AS15-Pa
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Figure A17. HP1100, positive mode, ESI-MS analysis of peptide AW9-Ma

Figure A18. HP1100, positive mode, ESI-MS analysis of peptide AW9-Pa
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Figure A19. HP1100, positive mode, ESI-MS analysis of peptide KS9-Ma

Figure A20. MALDI-TOF analysis of peptide GS9-Ma
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Figure A21. Negative mode, K5A

Figure A22. Positive mode, K6A
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Figure A23. Positive mode, KKAA

Figure A24. Positive mode, (FITC)KW10-Ma
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Figure A25. MALDI-TOF, positive mode, AK10(ALEXAFLUOR350)-Ma
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Appendix B. Chromatograms
Background
High pressure liquid chromatography (HPLC) is a highly advanced form of
chromatography that facilitates the separation of complex liquid mixtures. The separation of
mixture components is caused by differential attraction between the analytes, stationary phase,
and mobile phase. The instrument has four main components, mobile phase, the pump, the
stationary phase, and the detector. In combination with the many solvents available, the
different stationary phases can affect almost any kind of separation. C18 or octadecyl silane
(ODS) columns can be used for reverse phase separation and bare silica columns can be used
for normal phase separations. HPLC is compatible with many different detectors. Most
commonly, detectors are devices like photodiode array (PDA), dual wavelength detector, or
refractive index (RI). The capabilities of HPLC are multiplied when it is coupled with several
different detectors like UV-Vis and mass spectrometer. In the context of this work, HPLC was
used for two specific purposes. Preparative HPLC was used to purify large quantities of
peptide on the scale of hundreds of mg. Analytical HPLC was used to analyze the purity of
crude, in-process, and final peptides. Analytical separations were on the scale of 10 μg.
§B1. Analytical HPLC
Samples
Traces for samples K5A, K6A, KKAA, and (FITC)KW10-Ma were provided by the
manufacturer. All chromatograms shown were generated by analyzing finished product on the
Shimadzu Nexera i, 3D plus.
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Instrument configuration
Analytical chromatograms produced in house were recorded on the Shimadzu Nexera
– i LC-2040C 3D plus. A PDA was the detector. The A-line was milli-Q grade H2O + 0.1 %
v/v FA, the B-line was HPLC grade ACN + 0.1 % FA, the C-line was 60 % v/v ACN in H2O,
the D-line was MeOH + 0.1 % v/v FA. Waste was delivered to 5-gallon jug underneath the
instrument.
Sample prep
Peptides were dissolved in either buffered MeOH (humimycins) or 50 % (ACN+H2O
v/v) + 0.1 % v/v FA (AFPs). Samples were prepared at 0.5 – 2.0 mg/mL. Sample was gently
warmed for a few minutes to assist in dissolution of the solid analyte. The samples were
centrifuged to pack any undissolved solids to the bottom. The supernatant was filtered through
a 0.22 μm pore filter tip. Filtrate was loaded into an HPLC vial and inserted into the
autosampler rack.
Pump & autosampler
Flow rate was 1.0 mL/min, injection vol was 10 μL. Autosampler injection at
beginning of run. The gradient program is provided in Table B1. The mobile phase consisted
of water and acetonitrile.
Time (min)
0.01
2
5
30
35
Table B1. HPLC gradient program

%B
5
5
40
95
95
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Temperature controls
Autosampler = 25 °C. Column oven = 25 °C, PDA flow cell = 40 °C.
Column
Waters Xbridge Shield RP C18, 3.5 μ, 3.0 * 150 mm
Spectral parameters
Spectral window = 200 nm – 456nm. Resolution = 1 point per nm. Frequency = 30
Hz.
Data analysis
Signal from a solvent blank injection was subtracted from the experimental sample
injection to flatten the baseline and reduce noise. Channels for 220 and 280 nm were extracted
from the PDA data matrix. Peaks were manually integrated. Peaks below 5,000 area units
were disregarded as noise or combined with the nearest peak as a shoulder.
§B2. Preparatory HPLC parameters
Samples
All peptides were purified on the preparatory instrument to ensure ample yield at
reasonably high purity for the multitude of tests planned. This process was a bottleneck for
productivity due to the number of tedious steps required for any given sample.
Instrument configuration
A Varian Prep Star controlled by galaxy software on a PC running Windows XP was
used. A dual wavelength spectrometer was the detector. The A-line was Milli-Q grade H2O +
0.1 % v/v FA, the B-line was HPLC grade ACN + 0.1 % FA. Peaks of interest were collected
manually in 50 mL Falcon tubes and further analyzed for additional workup.
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Sample prep
Peptides were dissolved in 50 % (ACN+H2O v/v) + 0.1 % v/v FA. Samples were
slowly titrated with solvent until they were mostly dissolved. Sample was gently warmed for
a few minutes to assist in dissolution of the solid analyte. Centrifugation was carried out after
incubation followed by filtration through 0.5 μm pore filter tip. Filtrate was loaded into a 10
mL syringe and loaded into the injection loop.
Remaining parameters
Flow rate = 5.0 mL/min. Table B1 summarizes the gradient program used. Data was
recorded at the wavelengths of 220 nm and 280 nm and a frequency of 1 Hz. Injection loop
volume = 10 mL. Column = Phenomenex Luna 10, C18(2), 250 x 21.2 mm, 10 μ particle size.
Data processing and sample workup
Upon completing preparatory HPLC, fractions were individually characterized. Based
on these results, fractions were combined, concentrated on a rotary evaporator, acidified,
frozen in the -80 °C freezer, and lyophilized to dry powder using the freeze drier. The fractions
resulting from preparatory injections of the humimycin AMPs were analyzed using a UV-Vis
nanodrop spectrometer, ND1000, Thermo scientific. Fractions were combined based on
characteristic peaks at 220 nm and 280 nm, and long retention time in the preparatory column.
In-process humimycins samples were not analyzable on the in-house mass spectrometer due
to limitations relating to instrument configuration and the nature of the purified peptide
fractions. The in-process AFP samples were analyzed by the HP1100 mass spectrometer
followed by batch injections carried out on the Shimadzu analytical HPLC. In-process AFP
fractions were subsequently combined and worked up based on the presence of the target mass
in the mass spectra as well the analytical HPLC traces.
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§B3. Humimycins

Figure B1. 5A

Figure B2. 5B
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Figure B3. 5C

Figure B4. 6A
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Figure B5. 6B

Figure B6. 6C
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Figure B8. 7A
Figure B7. 6D
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§B4. Antifungal peptide

Figure B9. QY15

Figure B10. QY15-Ma
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Figure B11. AS15

Figure B12. AS15-Ac
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Figure B13. AS15-Ha

Figure B14. AS15-Da
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Figure B15. AS15-Ma

Figure B16. AS15-Pa
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Figure B17. K5A
Figure B18. K6A
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Figure B19. KKAA
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Figure B21. (FITC)KW10-Ma
Figure B20. AK10(ALEXAFLUOR350)-Ma
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Appendix C. Circular Dichroism Spectra
Background
CD spectroscopy measures the optical rotation of circularly polarized light at several
different wavelengths. This information provides clues to the secondary structure adopted by
the biomolecule in solution. Structures like α-helices and β-sheets are most distinctively
elucidated due to their recognizable CD spectra. Like absorbance in Beer’s law, the measured
rotation at each wavelength is a function of analyte concentration, path length, and the specific
rotation of the analyte at that wavelength. Unlike Beers law, the final values are reported in
millidegrees rotated.
The instrument has five key components, light source, monochromator, polarizer,
sample cell, and detector. The light source, typically a sodium or tungsten-halide lamp
generates a light beam that is then split up into its constituent wavelengths using the
monochromator. The monochromatic light is then polarized. The polarized light then passes
through the sample and is rotated by a small amount. The detector then generates a signal
based on the amount of rotation observed at each wavelength that is recorded on a nearby
computer. The in-house instrument used was the OLIS CD-spectrometer.
Samples
Not all samples were analyzed on the CD spectrometer. The acquisition time for a
spectra of the humimycins was prohibitively lengthy due to light scattering. DLS was
employed instead on these samples to characterize the nanoparticles causing the back
scattering. Only the first generation of AFP samples were analyzed on the CD spectrometer.
Shorter sequences were less likely to adapt a specific secondary structure not already achieved
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by its parent sequence found in generation one. Acquisition time for spectra of the AFP
samples were reasonable because no back scattering was present in this case.
Sample prep
A small amount of purified freeze-dried peptide was weighed out and diluted to 12.8
μg/mL using DMSO filtered through a sterile 0.22 μm filter tip. The peptide-DMSO stock
solution was diluted 100-fold in an Eppendorf tube using filtered Milli-Q water. This aqueous
mixture was serially diluted by factors of two until the desired concentration of 16 or 32 μg/mL
was achieved. Samples were loaded individually into a 300 μL quartz cuvette.
Data acquisition and processing
The spectral window was 200-300 nm, resolution of 1 point per nm. Scans were carried
out in triplicate and averaged. A blank scan was subtracted from the sample scan and plotted.
Excel was used to graph degrees of rotation as a function of wavelength in nm. The measured
angles of rotation were on the order of several millidegrees.
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§C1 Humimycin

Figure C1. CD spectra overlay of peptide 5B at 16 and 32 μg/mL.

Figure C2. CD spectra overlay of peptide 6A at 16 and 32 μg/mL.
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Figure C3. CD spectra overlay of peptide 6B at 16 and 32 μg/mL.

Figure C4. CD spectra overlay of peptide 6C at 16 and 32 μg/mL.
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Figure C5. CD spectra overlay of peptide 7A at 16 and 32 μg/mL.

Figure C6. CD spectra overlay of peptide 5B and 6C at 32 μg/mL.
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Figure C7. CD spectra overlay of peptide 6A and 7A at 16 μg/mL.
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§C2 AFP

Figure C8. CD spectra overlay of AS15.

Figure C9. CD spectra overlay of AS15-Ma.
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Figure C10. CD spectra overlay of QY15

Figure C11. CD spectra overlay of QY15-Ma
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Figure C12. CD spectra overlay of Sequence 1 peptides at 32 µg/mL

Figure C13. CD spectra overlay of Sequence 1 peptides at 16 µg/mL
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Figure C14. CD spectra overlay of Sequence 41 peptides at 32 µg/mL

Figure C15. CD spectra overlay of Sequence 41 peptides at 16 µg/mL
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Appendix D. Dynamic Light Scattering
Background
DLS is a technique that uses light scattering to detect Brownian motion of suspended
particles in solution. The correlated diffusion coefficient is then used to compute the reported
hydrodynamic diameter. There are six key components to this instrument. A laser is used to
illuminate the sample. The sample cell scatters light based on the Brownian motion of the
suspended particles. Brownian motion of the sample is a function of particle size, temperature,
and viscosity of the solvent. Scattered light then passes through an attenuator to alter the
amount of light received by the detector to prevent saturation. A detector is arranged at 90° or
173° from the source beam. Data from the detector is analyzed by an autocorrelator to
correlate intensity and rate of change of scattering light to the diffusion coefficient. A
computer is then used to make the final diameter calculations and report the data. Instrumental
analysis was provided by NJIT lab for material characterization.
Samples
A Malvern Zetasizer was used to determine the diameter of the humimycin
nanoparticles in aqueous solution. Several different humimycin versions and preparation
methods were tested. Most samples were analyzed after a 100-fold dilution of stock solution.
Sample prep
For conditions 1 and 2, freeze dried peptides were diluted to 12.8 mg/mL in filtered
DMSO. The first condition analyzed consisted of individual peptides diluted 100-fold in water
(v/v) for the final concentration of 128 µg/mL. The second condition analyzed the effect of
diluting two different peptide-DMSO stock solutions in the same aqueous mixture; the
operating concentration of each peptide was 128 µg/mL. The third condition analyzed the
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effect of pre-mixing the peptide-DMSO stock solutions of different peptides. Two different
peptides were diluted to 25.6 mg/mL in DMSO. 20 µL of each concentrated stock solution
was diluted 2-fold by mixing them. The concentration of each peptide in the working-DMSO
peptide solution was 12.8 mg/mL. The working solution was diluted 100-fold in water to form
the nanoparticle suspension.
§D1. Humimycins

Figure D1. Condition 1, 5A, 100 µg/mL
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Figure D2. Condition 1, 5A, 4 µg/mL

Figure D3. Condition 1, 5B, 85 µg/mL
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Figure D4. Condition 1, 5B, 4 µg/mL

Figure D5. Condition 1, 5C, 128 µg/mL
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Figure D6. Condition 1, 5C, 4 µg/mL

Figure D7. Condition 1, 6B, 128 µg/mL
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Figure D8. Condition 1, 6B, 4 µg/mL

Figure D9. Condition 1, 6C, 128 µg/mL
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Figure D10. Condition 1, 6C, 4 µg/mL

Figure D11. Condition 1, 7A, 256 µg/mL
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Figure D12. Condition 1, extruded liposome control.

Figure D13. Condition 2, 5A + 5B.
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Figure D14. Condition 3, 5A + 5B.

Figure D15. Condition 2, 5A + 7A.
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Figure D16. Condition 3, 5A + 7A.

Figure D17. Condition 2, 5B + 5C.
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Figure D18. Condition 3, 5B + 5C.

Figure D19. Condition 2, 5B + 6B.
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Figure D20. Condition 3, 5B + 6B.

Figure D21. Condition 2, 5B + 6C.
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Figure D22. Condition 3, 5B + 6C.
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Appendix E. UV-Vis spectra
Background
Ultra-violet visible spectroscopy measures the light absorbed by a molecule. Every
molecule has its own distinctive spectra that is a function of valence electron configuration.
The photon energy characteristic of UV-Vis spectra corresponds with valence electron
transition energy between ground states (HOMO) and excited states (LUMO). This differs
from other types of spectroscopies in the energy range and specific interactions analyzed. A
spectrometer has four main components, a light source, monochromator, sample cell, and
detector. The measure is reported as a unitless absorbance. The absorbance intensity is
proportional to the sample concentration, path length, and absorptivity coefficient, this is
called Beers law.
Samples
In-process humimycin samples were analyzed on the UV-vis nanodrop spectrometer
in high absorbance mode to help determine which fractions to combine and workup as finished
product. The decision to incorporate a specific fraction depended on retention time of the
fraction plus the presence of characteristic peaks indicative of peptide bonds and aromatic side
chains at 220 nm and 280 nm respectively. The shifted λmax observed is likely a consequence
of the high concentration of the peptide as well as solvent effects from the presence of a
significant amount of acetonitrile.
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§E1 Humimycins

Figure E1. UV-vis absorbance spectrum of peptide 5A

Figure E2. UV-vis absorbance of peptide 5B
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Figure E3. UV-vis absorbance of peptide 5C

Figure E4. UV-vis absorbance of peptide 6A

159

Figure E5. UV-vis absorbance of peptide 6B

Figure E6. UV-Vis absorbance of peptide 6C
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Figure E7. UV-Vis absorbance of peptide 6D

Figure E8. UV-Vis absorbance of peptide 7A
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Appendix F. Flow cytometry

Background
The annexin assay is an experiment used to analyze PS concentration. Annexin V is a
fluorophore labeled protein that can bind with PS on the outer membrane leaflet facilitating
the measurement via flow cytometry. In this experiment, alexafluor350 was used as the
annexin V fluorophore. Propidium iodide (PI) is a dye used as a viability indicator. Presence
of PI differentiates late-stage apoptotic cells from early-stage apoptotic cells. The instrument
used to carry out this experiment is called a flow cytometer. There are five key components
to this instrument. The injector introduces the sample to the flow cell at a chosen flow rate
produced by the pump. The cells are sorted in a cone of liquid formed in the flow cell and
counted by lasers. The nature of the cells analyzed are determined by their size and
morphology via force scatter (FSC) and side scattering (SSC) respectively. Lasers capable of
exciting various types of fluorophores are shined on the sample and the fluorescence of
corresponding fluorophores recorded. The sample then flows to a waste jug for hazardous
material disposal.
Samples
WT Cn was tested against AS15-Ma, AW9-Ma, K5A, K6A, KKAA in the presence of
alexafluor350 labeled Annexin-V peptide and propidium iodide. AW9-Ma was analyzed at
four different operating concentrations, 128, 64, 32, and 16 µg/mL. The other peptides were
tested only at 128 µg/mL. A negative control measurement lacking presence of a drug but still
maintained the annexin and PI was also recorded. Each sample was prepped in triplicate. To
optimize the data quantity and quality, 50,000 total events were recorded for each sample at a
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target rate of 50 – 100 cell/sec. The flow cytometer used was a MACS Quant from Miltenyi
Biotec.
Sample prep
Several different variations of this experiment were carried out to optimize the
measurement for reproducibility and data quantity. The procedure reported in the main text
was used to generate the data reported below. Initially this experiment was carried out with a
starting cell count of 1 x 105 – 2 x 105 cell per tube, however it was determined that using
more cells on the order of 1 x 106 cell per tube provided higher final cell counts and more
consistent data. In general, it was found that the fewer steps used, the more consistent the
results were. Each additional processing step cells undergo during sample prep allows for
compounding error to occur that greatly increased noise and variation in the measurements
and reduces final cell count. To this end, several additional washing steps originally included
the first several trials were omitted, and higher cell count resulted. All liquids used in this
experiment were warmed to room temperature prior to beginning. Samples were spun down
for five minutes in the micro centrifuge in the BSL2 room as needed. Upon spinning down
the cells, it is vital that the Eppendorf tubes were inspected visually each time to ensure that
the cells did in fact reform a cohesive plug at the bottom of the tube. If no cell plug was
observed, or not enough cells were pulled out of suspension, the tube was placed back in the
centrifuge for 5 additional minutes. During one trial run, the fixed cells in four percent
formaldehyde were diluted four-fold to one percent formaldehyde and analyzed instead of
spinning down the fixed cells before resuspending them in 1 % formaldehyde solution. It was
found that spinning down the cells after fixing in four percent formaldehyde helps to select
for whole cells in the analysis and reduce noise and debris. As soon as the cells were
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resuspended the final time in one percent formaldehyde at the end of sample prep, the
Eppendorf tubes were maintained on ice in a closed cooler until they were ready for injection
into the instrument.
Data acquisition
Each tube was vortexed for several seconds one final time just prior to injection to
ensure as many cells were suspended as possible. The pump was set to low flow rate for all
runs. The injector was set to 10 μL for calibration runs. Ten microliters of each sample were
injected into the instrument at first to calibrate the remaining injections for that sample. The
key data recorded on the calibration run was the cell count rate and total cell count. With these
data in hand, final dilutions of the sample with adequate concentration to achieve 50 – 100
cell/second and enough volume to yield 50,000 events were prepared. Events were triggered
by objects detected with at least 15 FSC-H. The experimental dilutions were prepared with at
least 10 % extra volume than what was computed to account for error. Channel V1 was used
to detect the alexafluor350 labeled annexin V. Channel B3 was used to detect the PI.
Data analysis
The data file (.mqd file) was transferred from the instrument to a flash drive for
analysis on a separate PC using the MACS Quant software provided by Miltenyi. The gating
strategy was provided by the manufacturer. The goal of gating the data is to refine it and
generate meaningful comparison between samples. Color of cell populations displayed on the
individual data sets are density maps of each population. The different colors correspond to
different population densities in the following order: Blue < green < yellow < red. Every
population is determined by parameters chosen by the operator. Table F1 below summarizes
the gating scheme used.
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Population 1 corresponds with every recorded event. The detector can be tuned to an
intensity threshold for a specific parameter which constitutes an event like FSC-H, FSC-A,
SSC-H, or SSC-A. The first result panel is a linear display of population one with the
dimensions of FSC-A verses FSC-H. Population two is gated along the diagonal, and
represents singlets, or cells that are not in the process of budding or cell division. Population
two is displayed in the second panel. The PI signal is logarithmic, and FSC-A is linear. This
panel is gated by population three which represents the viable population. This gate removes
cells with too high of a ratio of PI signal to cell size. Population three is displayed in the third
panel with linear dimensions of SSC-A verses FSC-A. Cells from panel three that have the
correct ratio of SSC-A and FSC-A is called population four and are considered to have the
correct morphology for the analysis in panel four and panel five.
Panel four shows population four in the logarithmic dimensions of PI-A verses
Annexin V-A. Cells that are low in PI signal and high in Annexin V signal are considered
positive results and counted in population five. Population five cells represent single, intact,
viable cells with the correct morphology that are high in Annexin signal and low in PI signal.
Panel five shows population four in the dimensions of linear FSC-A and logarithmic AnnexinV. Population six gated in panel five represent annexin V positive cells with the correct
morphology but doesn’t consider P.I signal beyond that of population 3 gate, viable cells.
Panel six is a histogram of population four. The Y axis is number of counts and the X axis is
annexin signal intensity. Several overlays are provided after the individual data sets to aid in
visualizing the general trends between samples and the relationships between the samples at
different stages of population gating.
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Population
number
1

Description

Every event captured by the flow cytometer, targeted 50,000 events per
injection
2
Singlets, gated from population 1
3
Viable population, gated from population 2
4
Morphology, gated from population 3
5
Negative for PI Positive for annexin V, gated from population 4
6
Positive for Annexin V, gated from population 4
Table F1. Description of gating strategy used to analyze the annexin assay data.
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§F1 AFP annexin V assay
Individual samples

Figure F1. Experiment 5, sample 1.1, AW9-Ma, 16 µg/mL.
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Figure F2. Experiment 5, sample 1.2, AW9-Ma, 16 µg/mL.
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Figure F3. Experiment 5, sample 1.3, AW9-Ma, 16 µg/mL.
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Figure F4. Experiment 5, sample 2.1, AW9-Ma, 32 µg/mL.
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Figure F5. Experiment 5, sample 2.2, AW9-Ma, 32 µg/mL.
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Figure F6. Experiment 5, sample 2.3, AW9-Ma, 32 µg/mL.
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Figure F7. Experiment 5, sample 3.1, AW9-Ma, 64 µg/mL.
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Figure F8. Experiment 5, sample 3.2, AW9-Ma, 64 µg/mL.
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Figure F9. Experiment 5, sample 3.3, AW9-Ma, 64 µg/mL.
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Figure F10. Experiment 5, sample 4.1, AW9-Ma, 128 µg/mL.
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Figure F11. Experiment 5, sample 4.2, AW9-Ma, 128 µg/mL.
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Figure F12. Experiment 5, sample 4.3, AW9-Ma, 128 µg/mL.
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Figure F13. Experiment 6, sample 1.1, K5A, 128 µg/mL.
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Figure F14. Experiment 6, sample 1.2, K5A, 128 µg/mL.
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Figure F15. Experiment 6, sample 1.3, K5A, 128 µg/mL.
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Figure F16. Experiment 6, sample 2.1, K6A, 128 µg/mL.
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Figure F17. Experiment 6, sample 2.2, K6A, 128 µg/mL.
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Figure F18. Experiment 6, sample 2.3, K6A, 128 µg/mL.
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Figure F19. Experiment 6, sample 3.1, KKAA, 128 µg/mL.
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Figure F20. Experiment 6, sample 3.2, KKAA, 128 µg/mL.
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Figure F21. Experiment 6, sample 3.3, KKAA, 128 µg/mL.
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Figure F22. Experiment 6, sample 4.1, AS15-Ma, 128 µg/mL.
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Figure F23. Experiment 6, sample 4.2, AS15-Ma, 128 µg/mL.
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Figure F24. Experiment 6, sample 4.3, AS15-Ma, 128 µg/mL.
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Figure F25. Experiment 6, sample 5.1, no peptide control.
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Figure F26. Experiment 6, sample 5.2, no peptide control.
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Figure F27. Experiment 6, sample 5.3, no peptide control.
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Overlays

Figure F28. Overlay of population 4 between cells incubated with AW9-Ma, AS15-Ma, at
128 µg/mL and baseline samples. Cells with low PI signal, and high annexin V signal are
considered a positive result and are included in population 5 indicated by the green box. The
cutoffs of this gate were chosen such that approximately two thirds of cells from population
4 were included in population 5 for the most potent inhibitor, AW9-Ma at the maximum tested
concentration.
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Figure F29. Histogram overlay of alanine substituted peptides and the baseline. The
histogram depicts the number of counts as a function of annexin V signal intensity from
population 4, the morphology gate. Heavy smoothing was applied
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Figure F30. Histogram overlay of AW9-Ma, AS15-Ma, and the baseline. This figure depicts
the number of counts as a function of annexin V signal intensity from population 4, the
morphology gate. Heavy smoothing was applied.

196

Figure F31. Histogram overlay of AW9-Ma, AS15-Ma, and the baseline. This figure depicts
the number of counts as a function of annexin V signal intensity from population 5.
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Figure F32. Histogram overlay of alanine substituted peptides and the baseline. The
histogram depicts the number of counts as a function of annexin V signal intensity from
population 5.
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Figure F33. Histogram overlay of AW9-Ma, AS15-Ma, and the baseline. This figure depicts
the number of counts as a function of annexin V signal intensity from population 6.
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Figure F34. Histogram overlay of alanine substituted peptides and the baseline. The
histogram depicts the number of counts as a function of annexin V signal intensity from
population 6.
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Appendix G. Permissions
Figure G1. Permission to use the humimycins article from the journal Peptide Science
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Figure G2. Permission to use the antifungal peptide article from the journal Microbiology
Spectrum
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Figure G3. Permission to use the protein structure of ATP11C-Cdc50a
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